



# NATIONAL CANCER REGISTRY

Division of the National Health Laboratory Service



health

Department:  
Health  
REPUBLIC OF SOUTH AFRICA

---

# EKURHULENI POPULATION- BASED CANCER REGISTRY 2023 REPORT

---

Johannesburg, South Africa, March 2025

**Copyright © 2025**

**Citation:**

**National Cancer Registry, South Africa. Ekurhuleni Population-Based Cancer Registry  
2023 Report. [www.ncr.ac.za](http://www.ncr.ac.za).**

**Compiled by:**

Babongile Ndlovu (Epidemiologist)

Dr Judith Mwansa-Kambafwile (Senior Epidemiologist)

Dr Mazvita Muchengeti (Head of Department)

**Ekurhuleni Population-Based Cancer Registry Surveillance Officers:**

Clarence Sibiya

Londiwe Nyembe

Mapule Makama

Nelisiwe Fakude

Nomthandazo Dube

Phelade Kale

Simphiwe Javu

Sphiwe Mpangani

Ekurhuleni Population-Based Cancer Registry

National Cancer Registry, National Health Laboratory Service

1 Modderfontein Road, Sandringham

Johannesburg

South Africa

2131

Tel: +27 11 555 0548

Fax to email: +27 11 386 6516

Website: [www.ncr.ac.za](http://www.ncr.ac.za)

## **DISCLAIMER**

This report includes all reported cancer cases for Ekurhuleni residents diagnosed from 1<sup>st</sup> January 2023 to 31<sup>st</sup> December 2023 as recorded in the Ekurhuleni population-based cancer registry (EPBCR). The information reflects the data at the time of closing the 2023 database for cleaning and analysis on the 28<sup>th</sup> of January 2025. The EPBCR continues to receive and collect additional data; therefore, the data may be updated as and when necessary. Special requests for data should be directed to the NCR administrator, Ms Hellen Mathabatha, [HellenM@nicd.ac.za](mailto:HellenM@nicd.ac.za).

## TABLE OF CONTENTS

DISCLAIMER .....	iii
TABLE OF CONTENTS.....	iv
LIST OF TABLES .....	v
<b>LIST OF FIGURES .....</b>	<b>v</b>
<b>LIST OF APPENDICES .....</b>	<b>v</b>
FOREWORD .....	viii
EXECUTIVE SUMMARY .....	ix
INTRODUCTION .....	1
METHODS .....	4
<b>Data sources.....</b>	<b>4</b>
<b>Data collection and processes.....</b>	<b>7</b>
<b>Confidentiality.....</b>	<b>9</b>
<b>Statistical analysis .....</b>	<b>10</b>
RESULTS .....	11
<b>Overall cancer incidence .....</b>	<b>11</b>
<b>Comparison with the years 2017, 2018, 2019, 2020, 2021, 2022 &amp;2023 .....</b>	<b>17</b>
<b>Childhood cancer incidence .....</b>	<b>20</b>
<b>Data Quality Indicators.....</b>	<b>21</b>
DISCUSSION .....	23
CONCLUSION.....	25
ACKNOWLEDGEMENTS.....	26
REFERENCES .....	28
APPENDICES .....	30

## **List Of Tables**

Table 1: Summary Statistics for all Cancers In Men, EPBCR 2023 .....	12
Table 2: Summary Statistics for all Cancers In Women, EPBCR 2023 .....	13
Table 3: Childhood Cancers, EPBCR 2023 .....	20
Table 4: Percentage of Cases Morphologically Verified (MV), Diagnosed Clinically Or Diagnosed By Death Certificate Only (DCO), EPBCR 2023.....	21

## **LIST OF FIGURES**

Figure 1: Ekurhuleni population-based cancer registry data sources map, 31 December 2023	6
Figure 2: Ekurhuleni population-based cancer registry data flow diagram, 2017-2023.....	8
Figure 3: Percentage of cancer cases by sex and population group, EPBCR 2023. ....	11
Figure 4: Frequency of most common cancers in males, EPBCR 2023 .....	14
Figure 5: Age standardised incidence rates for most common cancers in males, EPBCR 2023 .....	15
Figure 6: Frequency of most common cancers in females, EPBCR 2023.....	15
Figure 7: Age-standardised incidence rates for common cancers in females, EPBCR 2023 ..	16
Figure 8: ASR for top 5 cancers in men by population group, EPBCR 2023 .....	16
Figure 9: ASR for top 5 cancers in women by population group, EPBCR 2023 .....	17
Figure 10: ASRs for most common cancers in men, 2017-2023 .....	18
Figure 11: ASRs for most common cancers in women, 2017-2023 .....	18
Figure 12: Number of cancer cases reported by year and sex, EPBCR 2017-2023 .....	19

## **LIST OF APPENDICES**

Appendix 1: list of data sources.....	30
Appendix 2: Suth African cancer notification form .....	32
Appendix 3: Tables of incidence by site, sex, age group and population, 2023.....	33

## ACRONYMS AND ABBREVIATIONS

AFCRN	: African Cancer Registry Network
ASR	: Age-Standardised Incidence Rate
BCC	: Basal Cell Carcinoma
CIDERU	: Cancer & Infectious Diseases Epidemiology Research Unit
CIDERU	: Cancer and Infectious Disease Epidemiology Research Unit
CNS	: Central Nervous System
COVID-19	: Coronavirus Disease 2019
DHA	: Department of Home Affairs, South Africa
DoH	: Department of Health, South Africa
ECCR	: Eastern Cape Cancer Registry
EPBCR	: Ekurhuleni Population-Based Cancer Registry
GICR	: Global Initiative for Cancer Registry Development
IACR	: International Association of Cancer Registries
IARC	: International Agency for Research on Cancer
ICCC	: International Classification of Childhood Cancer
ICDO-3	: International Classification of Diseases for Oncology Third Edition
INCTR	: International Network for Cancer Treatment and Research
KZN PBCR	: KwaZulu-Natal Population-Based Cancer Registry
KZN	: KwaZulu-Natal
LMIC	: Low- or Middle-Income Country
NCDs	: Non-Communicable Disease
NCR	: National Cancer Registry, South Africa
NHLS	: National Health Laboratory Service

PBCR : Population-Based Cancer Registry

POPI Act : Protection of Personal Information Act, South Africa

SA : South Africa

SACCSG : South African Children's Study Cancer Group

SAMRC : South African Medical Research Council

SAOC : South African Oncology Consortium

STATSSA : Statistics, South Africa

UICC : Union for International Cancer Control

UP : University of Pretoria

WHO : World Health Organization

WSP : World Standard Population




## FOREWORD

It gives me great pleasure to make public the 2023 annual report of the Ekurhuleni Population-Based Cancer Registry (EPBCR).

The current report on the EPBCR culminates from support from the National Institute for Communicable Diseases, the National Health Laboratory Service, and the work of the National Cancer Registry (NCR). This is the seventh report to be produced for the EPBCR; previous reports have covered the years 2017 to 2022. While this report provides essential information for healthcare planning locally, the vision for the EPBCR has always been to reach benchmark international standards to report South Africa's cancer incidence rates to the International Agency for Research on Cancer (IARC). With each successive year of operations, the EPBCR has achieved progressively better data quality.

In the 2024/2025 financial year, following the COVID-19 pandemic, access to hospitals for surveillance officers has significantly improved. The challenges posed by load shedding, which previously hindered cancer surveillance efforts, have lessened. In the past, power outages and ongoing network connectivity issues in certain healthcare facilities impacted our work. I would like to commend the EPBCR staff and stakeholders for their continued dedication to cancer surveillance during these challenging times.



Dr Mazvita Muchengeti

**(Head of the Department, National Cancer Registry)**

Date: 31 March 2025

## EXECUTIVE SUMMARY

The 2023 cancer incidence report from the Ekurhuleni Population-Based Cancer Registry (EPBCR) marks the seventh year of comprehensive cancer surveillance since its establishment, following the enactment of Regulation No. 380 of the National Health Act. This regulation mandates that cancer is a reportable disease, requiring healthcare workers to report confirmed cases to the National Cancer Registry (NCR). The EPBCR serves as a crucial pilot site for population-based cancer registration in South Africa, contributing vital data for policy-making and intervention programmes.

In 2023, a total of 3,978 new cancer cases were registered, reflecting a 3% decrease from 2022. Among these, 1,659 (41.7%) were in males, and 2,319 (58.3%) in females, with the most common cancers being prostate, colorectal, lung, and non-Hodgkin lymphoma in males, and breast, cervical, colorectal, and uterine cancers in females. Notably, the White population exhibited the highest incidence rates across most cancers, highlighting disparities in healthcare access that affect diagnosis and treatment, particularly for the Black population.

Paediatric cancers accounted for 0.9% of all cases, with 37 cancers registered among children, predominantly nephroblastoma and CNS neoplasms. The report indicates that the overall percentage of morphologically verified cases was 88.7%, underscoring the EPBCR's commitment to high-quality data collection. However, challenges remain, including a significant number of cases with unspecified primary sites and the impact of the NHLS hack on data collection processes.

The NCR continues to strengthen its initiatives, including the integration of the Eastern Cape Cancer Registry and the support for the newly launched KwaZulu-Natal Population-based Cancer Registry (KZN PBCR). Enhanced collaboration with the private sector, including partnerships with the South African Oncology Consortium and Icon Oncology, aim to improve data access and quality, ensuring a more comprehensive understanding of cancer incidence.

This report provides critical insights for stakeholders to inform decision-making, planning of cancer initiatives, and evaluation of health interventions, ultimately contributing to the reduction of cancer incidence and mortality rates in South Africa. The NCR remains committed to expanding PBCRs and enhancing data quality to better address the cancer burden in the population.

## INTRODUCTION

Cancer remains an important public health challenge and the second leading cause of death globally (1). In 2022, the World Health Organisation (WHO), International Agency for Research on Cancer (IARC) reported an estimated 20 million new cancer cases and about 9.7 million deaths worldwide (2). The distribution of cancer incidence and mortality vary significantly across different regions of the world. Low and middle-income countries (LMICs) are greatly affected and it is estimated that in 2040 about two-thirds of new cancer cases will originate in LMICs (3). The economic implications of the increasing cancer incidence and deaths are catastrophic to both individuals in the community and to the public health system (4). Proper evidence-based planning for the future to effectively inform cancer prevention and control policies, intervention programmes and strategies, depends on robust continuous cancer surveillance with quality data (3). It was recognised by many governments during the 2011 United Nations resolution on Non-Communicable Diseases (NCDs) and WHO Global Action for the prevention and control of NCDs for 2013-2020, that population-based cancer registries (PBCRs) are vital components for cancer prevention and control (5). Population-based cancer registries gather information about all cancer cases and deaths for residents within well-defined geographical areas over some time (6). Population-based cancer registries are the most reliable tool for accurately estimating the true burden of cancer. They play a crucial role in monitoring epidemiological trends and forecasting the future cancer burden of a country (6).

In 2011, the IARC in partnership with international communities launched the Global Initiative for Cancer Registry Development (GICR) to accelerate PBCR coverage and quality data improvements across the globe (7). Despite the efforts made by the IARC, there are an estimated 700 cancer registries across the world which cover only about 21% of the world's population (8). In the African region, the PBCR coverage is estimated at 11%. To improve PBCRs coverage and effectiveness of cancer surveillance in sub-Saharan Africa, the International Network for Cancer Treatment and Research (INCTR) established and launched the African Cancer Registry Network (AFCRN) in 2012 (8).

The South African government has made efforts to support the development of PBCRs in the country. In 2011, the South African Department of Health enacted Regulation No. 380 of the National Health Act (Act 61 of 2003), which formally established the National Cancer Registry

(NCR) as its delegated agency for the collection of cancer surveillance information (3). This regulation made cancer a reportable disease with every healthcare worker obliged to report confirmed cancers to the NCR (3,4). In addition, it mandated the NCR to establish PBCR for the country. After consultation with local and international cancer surveillance experts, it was decided that a minimum of four population-based cancer registries will be required to confidently extrapolate national cancer incidence. The NCR established the Ekurhuleni Population-Based Cancer Registry (EPBCR) in Gauteng, as the first urban population-based cancer surveillance site in the country in 2017.

The KwaZulu-Natal Population-Based Cancer Registry (KZN PBCR), launched in February 2023 in partnership with the Cancer & Infectious Diseases Epidemiology Research Unit (CIDERU) at the University of KwaZulu-Natal (UKZN), is publishing its first report on cancer incidence in the Ethekewini district for 2023 concurrently with this report. The NCR has been providing ongoing technical support to the KZN PBCR, including assistance with data collection techniques, management, and analysis. Additionally, the EPBCR and KZN PBCR presented their cancer registry data at the 2024 AFCRN meeting in Cape Town, where cancer registries from across Africa showcased their work and exchanged insights on new developments and cancer registration processes to implement in their registries.

The NCR is considering the possibility of integrating the Eastern Cape Cancer Registry (ECCR) and providing it with technical support. This financial year, one cancer surveillance officer was assigned to the ECCR to assist with data collection activities at Nelson Mandela Academic Hospital. Discussions with the Western Cape Province began in 2023 regarding the establishment of a third PBCR. The NCR is committed to enhancing the PBCR by ensuring that its data complies with international standards. Additionally, the NCR will continue to implement other PBCRs in South Africa while focusing on capacity building and strengthening relationships with stakeholders.

The NCR has improved its collaboration with the private sector, including the South African Oncology Consortium (SAOC) and Icon Oncology, to ensure comprehensive access to data from private sector sources. The EPBCR has incorporated data from SAOC and Icon in its

2023 report. Additionally, the KZN PBCR has included Icon data for 2023 and is in discussions with SAOC to obtain data in the near future.

This is the seventh cancer incidence report for the EPBCR accounting for all reported cancers diagnosed in 2023.

## **METHODS**

The EPBCR employs cancer registration guidelines and strategies developed by the International Association of Cancer Registries (IACR), the International Agency for Research on Cancer (IARC) and the African Cancer Registry Network (AFCRN). The EPBCR employs both passive (receives reports from facilities) and active surveillance (sends surveillance officers to facilities collect information from different sources), collecting data on all cancer patients residing in Ekurhuleni metropolitan municipality diagnosed by clinical, radiological, pathology or any other means of investigation.

### **Data sources**

#### **i. Government and Private Hospitals/Healthcare Facilities**

The EPBCR has multiple data sources. The data sources extend beyond the borders of the Ekurhuleni metropolitan municipality due to the nature of the South African healthcare referral system. The municipalities do not often have all levels of care (level 1: Primary healthcare clinic, Community healthcare centre, District hospital, level 2: Regional hospital, level 3: Provincial tertiary hospital, and level 4: Central hospital and Specialised hospital) within its borders (9). Therefore, patients may be referred out of the municipality to access further diagnosis and management. Secondly, South African patients are a highly mobile population and have the freedom to choose the healthcare facility they prefer, which may not necessarily be within the borders of the district in which they reside.

In addition to the public healthcare facilities, South Africa also has a large and well-resourced private healthcare industry. Sixteen per cent of the South African population has medical health insurance and is thus able to access healthcare in private healthcare facilities. Therefore, to obtain complete reporting from the Ekurhuleni District's population, the EPBCR also collects data from private hospitals, and clinicians in independent private practice (See Appendix 1 for a comprehensive list of data sources).

#### **ii. Laboratories, Oncology Networks and Associations**

SA has an expansive network of both public and private laboratories. An estimated 80% of the SA's population is serviced by NHLS, which has over 200 laboratories in nine provinces of SA (10). The other estimated 20% of the population is covered

by private laboratories which include but are not limited to Ampath, Pathcare and Lancet laboratories. Both public and private laboratories send electronic reports of patients diagnosed with cancer to the NCR's national pathology surveillance programme. The surveillance officers use all the pathology reports received from laboratories together with other data tools (medical files, hospital register, pharmacy list etc.) to identify, trace and register patients from Ekurhuleni metropolitan municipality into the EPBCR.

In addition, Icon Oncology and the South African Oncology Consortium (SAOC) report their relevant data for residents of Ekurhuleni to the NCR. The surveillance officers use these data sources to consolidate missing information for patients already registered in the EPBCR database or to trace and notify the patient in conjunction with other data tools from different data sources. Finally, surveillance officers use hospital registers, patient files and mortuary records to identify new patients not already recorded in an existing database available to the NCR.

**iii. The Hospice**

The surveillance officers visit hospices at regular intervals to consolidate information missing for patients already registered from other data sources such as hospitals, as well as to report any new patients identified.

**iv. Vital Statistics (Death Registration)**

The Department of Home Affairs (DHA) is the custodian of vital statistics for SA. Statistics South Africa (STATS SA) also has cleaned vital statistics data for South Africans that can be used to consolidate vital status (i.e. dead/alive) in the EPBCR. However, STATS SA is unable to legally share identifiable patient-level data with other official organisations. To compensate for the challenge, the surveillance officers visit the mortuaries within healthcare facilities to trace and report cases of cancer for patients who may have been missed while alive.

Figure 1 below illustrates the spatial distribution of the data sources for EPBCR as of 31 December 2023.




Figure 1: Ekurhuleni population-based cancer registry data sources map, 31 December 2023



## Data collection and processes

The EPBCR uses both active and passive methods of case finding.

Active case finding:

- The surveillance officers visit healthcare facilities to review electronic and or physical records of patients such as patient files, admission registers, pathology reports, radiology reports, death registers, outpatient registers, pharmacy registers and clinicians' statistical records to notify confirmed cancer cases on the cancer notification forms.

Passive case finding:

- As mentioned above, both the Icon Oncology and the South African Oncology Consortium (SAOC) passively provide data to the NCR for the Ekurhuleni district.
- Data is also extracted from the national pathology registry (both public and private sector data) to supplement the EPBCR dataset.

Inclusion criteria for both active and passive case-finding methods:

- All confirmed cancer cases, in persons who are residents of the Ekurhuleni metropolitan municipality, diagnosed from 1<sup>st</sup> January to 31 December of the relevant year must be reported to the registry.
- Cancer cases include:
  - Cases considered malignant in the morphology section of the International Classification of Diseases for Oncology (ICD-O); behaviour code-3 are reported to the registry.
  - Cancers in metastatic sites (for example, lymph nodes) are registered with the primary tumour site topography. If this is not known, it is registered as an unknown primary site.

The surveillance officers extract data/variables required (See Appendix 2: South African Cancer Registration Form) from data sources such as medical records and code the cancer diagnosis according to the International Classification of Diseases for Oncology 3<sup>rd</sup> edition (ICDO-3) for topography and morphology. A pathology report, where available, is filed with the corresponding notification form. Reports are filed according to the date and facility of diagnosis.

The files are then captured onto the RedCap system. The NCR uses REDCap instead of the IARC-recommended CanReg system because CanReg did not meet the current data processing requirements, such as large storage capacity, simultaneous multiple users and virtual network use.




Figure 2: Ekurhuleni Population-Based Cancer Registry data flow diagram, 2017-2023

The captured files are sent to the surveillance manager for quality assurance and quality control. The surveillance manager uses both the physical notification forms and electronic records on Redcap for each cancer case to check for duplicates, completeness, and consistency. The files are stored in a locked cabinet for 20 years as per the South Africa Protection of Personal Information Act (POPI Act ) before they are permanently destroyed (11). The complete, quality-assured dataset is extracted per year (1<sup>st</sup> January to 31<sup>st</sup> December for each year) for cleaning and analysis using Stata software. The analyzed data is then used for annual incidence reports, teaching/training, and research purposes. Figure 2, above illustrates the data processing and flow for the EPBCR.

## **Confidentiality**

The NCR adheres to the NHLS, the IARC/IACR guidelines and the POPI Act to ensure the preservation of privacy during the EPBCR surveillance process (11). Request to use de-identified individual-level EPBCR data by entities/individuals is sought in writing to the NCR and applying for data through the NHLS Academic Affairs and Research Management System (<https://aarms.nhls.ac.za/>). Ethics approval is required before data is granted. Cancer statistics are released in an aggregated format through the annual reports published on the NCR website <https://www.nicd.ac.za/centres/national-cancer-registry/>.

## Statistical analysis

The results are presented as:

- the number of new cancer cases,
- the percentage of all new cancer cases,
- Age-standardised incidence rate (ASR) per 100,000 and
- The lifetime risk

The results are further stratified by:

- sex (Male and Female),
- population group (Black, White, Asian and Coloured) and
- age groups (5-year interval, e.g.0-5 years, 5-10, 10-15, etc.).

For age standardization, the Segi World Standard Population (WSP) is used as per international cancer registration norms. STATS SA 2023 mid-year population data for Ekurhuleni metropolitan municipality was used as a denominator.

The calculation methods are as follows:

$$\text{Crude} = \frac{\text{Number of new cases}}{\text{Mid-year population}} \times 100,000$$

$$\text{WSP weighting} = \frac{\text{WSP (for each age group)}}{\text{Total WSP for all age groups}} \times 100,000$$

$$\text{ASR} = \text{Crude} \times \text{WSP weighting}$$

## RESULTS

### Overall cancer incidence

A total of 3,978 cancer cases were registered by the EPBCR for the year 2023, with 1659 cases (41.7%) occurring in males and 2319 (58.3%) occurring in females. Benign growths, in-situ lesions and cancers of unknown behaviour were excluded from the data collection and analysis.

Figure 3 below shows the percentage of cancer cases diagnosed in 2023 by sex and population group. Sixty-one per cent of cases were diagnosed among the Black population, 35% among the White population, while 2% was diagnosed among the Coloured and Asian population groups, respectively.




Figure 3: Percentage of cancer cases by sex and population group, EPBCR 2023.

Tables 1 and 2 illustrate a detailed tabulation of cases registered in 2023 for males and females. The tables show the total number of cases registered, crude rates per 100 000 population, age-adjusted incidence rates per 100 000 population, cumulative and lifetime risk for each cancer. Appendix tables further elaborate on these data by demonstrating frequency, age-standardised and age-specific incidence rates by population group and sex.

Table 1: Summary statistics for all cancers in Men, EPBCR 2023

<b>SITE</b>	<b>N*</b>	<b>CRUDE RATE</b>	<b>ASR</b>	<b>CUM RISK 0-74</b>	<b>LIFETIME RISK 0-74</b>
All sites	1659	43,94	47,12	5	9
All sites but skin	1573	41,67	44,59	5	10
Prostate	637	16,87	18,71	2	22
Colorectal	137	3,63	3,80	1	110
Lung	88	2,33	2,46	0	167
Primary site unknown	80	2,12	2,16	0	213
Oesophagus	68	1,80	1,91	0	201
Non Hodgkin lymphoma	62	1,64	1,69	0	298
Liver & Bile duct	45	1,19	1,23	0	290
Stomach	40	1,06	1,08	0	400
BCC	37	0,98	1,14	0	457
Melanoma	36	0,95	1,11	0	325
Larynx	35	0,93	0,98	0	410
SCC of Skin	31	0,82	0,89	0	471
Kidney	28	0,74	0,84	0	530
Pancreas	28	0,74	0,79	0	437
Bladder	25	0,66	0,73	0	717
Naso-Oropharynx	20	0,53	0,60	0	903
Penis	20	0,53	0,54	0	840
Skin other	18	0,48	0,49	0	1007
Kaposi Sarcoma	18	0,48	0,45	0	1164
Anus	17	0,45	0,41	0	1102
Hodgkin lymphoma	17	0,45	0,40	0	1151
Brain, CNS	16	0,42	0,44	0	1016
Leukaemia	16	0,42	0,41	0	1098
Mouth	14	0,37	0,41	0	1606
Myeloma	14	0,37	0,38	0	1201
Connective tissue	14	0,37	0,38	0	1145
Tongue	13	0,34	0,36	0	1039
Breast	12	0,32	0,37	0	1041
Other specified	12	0,32	0,33	0	1070
Testis	8	0,21	0,18	0	2189
Mesothelioma	7	0,19	0,24	0	4797
Haematology other	7	0,19	0,21	0	2790
Ill defined	7	0,19	0,19	0	3697
Salivary gland	6	0,16	0,17	0	3993
Small intestine	6	0,16	0,16	0	2862
Eye	5	0,13	0,12	0	3547
Thyroid	4	0,11	0,10	0	4663
Endocrine	4	0,11	0,09	0	6579
Bone	3	0,08	0,09	0	9434
Burkitt lymphoma	2	0,05	0,05	0	8197
Gum	1	0,03	0,03	0	12904
Lip	1	0,03	0,02	0	29412

Table 2: Summary statistics for all cancers in Women, EPBCR 2023

SITE	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites	2319	56,91	61,19	7	8
All sites but skin	2242	55,02	58,80	7	9
Breast	648	15,91	16,88	2	28
Cervix	572	14,04	13,58	2	35
Colorectal	134	3,29	3,77	0	114
Primary site unknown	107	2,63	2,99	0	163
Uterus	97	2,38	2,94	0	130
Vulva	95	2,33	2,06	0	263
Lung	49	1,20	1,60	0	353
Ovary	44	1,08	1,19	0	375
Liver & Bile duct	43	1,06	1,25	0	328
Melanoma	36	0,88	1,10	0	420
Oesophagus	34	0,83	0,96	0	571
Non Hodgkin lymphoma	33	0,81	0,84	0	529
BCC	32	0,79	1,02	0	550
Pancreas	31	0,74	0,89	0	739
SCC of Skin	28	0,69	0,86	0	533
Anus	26	0,64	0,59	0	1093
Stomach	23	0,56	0,69	0	666
Leukaemia	21	0,52	0,69	0	724
Brain, CNS	21	0,52	0,61	0	907
Bladder	20	0,49	0,64	0	1001
Kidney	19	0,47	0,51	0	1091
Mouth	18	0,44	0,49	0	1274
Skin other	17	0,42	0,50	0	736
Other specified	17	0,42	0,47	0	1257
Thyroid	17	0,42	0,40	0	1403
Myeloma	14	0,34	0,41	0	1783
Hodgkin lymphoma	14	0,34	0,34	0	1861
Vagina	12	0,29	0,33	0	1755
Naso-Oropharynx	11	0,27	0,30	0	2144
Tongue	11	0,27	0,26	0	2077
Kaposi Sarcoma	10	0,25	0,18	0	1597
Ill defined	9	0,22	0,25	0	2802
Connective tissue	9	0,22	0,23	0	2133
Eye	8	0,20	0,21	0	1785
Haematology other	7	0,17	0,28	0	2268
Small intestine	7	0,17	0,26	0	3566
Endocrine	7	0,17	0,16	0	3285
Larynx	5	0,12	0,13	0	2535
Lip	3	0,07	0,07	0	5989
Placenta	3	0,07	0,07	0	10870
Salivary gland	3	0,07	0,07	0	9524
Mesothelioma	2	0,05	0,06	0	3206

Bone	1	0,02	0,03	0	12904
Burkitt lymphoma	1	0,02	0,02	0	21053

Figure 4-7 below illustrates the frequency and age-standardised incidence rates of the most common cancers registered in the EPBCR in 2023 for males and females. Prostate cancer was by far the most common cancer amongst men with 637 cases and an ASR of 18.71/100 000 population. Amongst women, breast cancer was leading with 648 new cases reported with an ASR of 16.88/100 000. Figures 8 and 9 illustrate the top 5 cancers ASRs by population group. In males, the White population group had the highest ASR in prostate cancer followed Black, Asian then coloured. In females, the White population group had the highest ASR in breast cancer, followed by Black, Asian then Coloured.




Figure 4: Frequency of most common cancers in males, EPBCR 2023






Figure 5: Age Standardised Incidence Rates for most common cancers in males, EPBCR 2023




Figure 6: Frequency of most common cancers in females, EPBCR 2023




Figure 7: Age-standardised incidence rates for common cancers in females, EPBCR 2023




Figure 8: ASR for top 5 cancers in men by population group, EPBCR 2023




Figure 9: ASR for top 5 cancers in women by population group, EPBCR 2023

### Comparison of cancer incidence across the years 2017- 2023

Figures 10 and 11 show a comparison of ASRs for common cancer cases from 2017 to 2023 by sex. Figure 12 shows comparisons of case numbers from 2017 to 2023. There was a 3% decrease in the number of cancer cases reported in 2023 (n=3978) vs the year 2022 (n=4116). Among males, there was a 5% decrease from 1741 in 2022 while among females there was a 2% decrease from 2375 in 2022. The pattern of the most common top 5 cancers age-standardised incidence rates by sex remained comparable between 2017 and 2023 with a slight decrease in incidence.




Figure 10: ASRs for most common cancers in men, 2017-2023




Figure 11: ASRs for most common cancers in women, 2017-2023




Figure 12: Number of Cancer cases reported by year and sex, EPBCR 2017-2023

## Childhood cancer incidence

Table 3 below shows the top 10 cancers in children aged 0-14 years in the Ekurhuleni area. Thirty-seven cancers were registered in 2023 among children. Paediatric cancers accounted for 0.9% of all cancers registered in 2023. There were 11 cancers in boys and 26 cancers in girls. Nephroblastoma, CNS neoplasms, lymphoma, neuroblastoma and retinoblastoma were the most common cancers in children.

Table 3: Childhood cancers, EPBCR 2023

Cancer	Number of cases				M/F ratio	Rates per Million Age-Specific Rates			Crude	ASR	LCL	UCL
	Age 0-4	Age 5-9	Age 10-14	All Ages		Age 0-4	Age 5-9	Age 10-14				
Lymphoma	1	1	1	3	1	3	3	3	3,11	3,11	0,63	9,12
CNS Neoplasms	4	0	2	6	1	12	0	6	6,22	6,55	2,38	14,21
Neuroblastoma	2	0	0	2		6	0	0	2,07	2,37	0,29	8,21
Retinoblastoma	1	0	0	1		3	0	0	1,04	1,18	0,03	6,20
Nephroblastoma - Wilms Tumour	4	4	0	8	1	12	13	0	8,30	8,79	3,78	17,24
Other, specified	11	3	3	17	0	34	9	9	17,64	18,79	10,91	30,03
<b>All sites</b>	<b>23</b>	<b>8</b>	<b>6</b>	<b>37</b>	<b>3</b>	<b>70</b>	<b>25</b>	<b>19</b>	<b>38,39</b>	<b>40,79</b>	<b>18,03</b>	<b>104,22</b>

## Data Quality Indicators

### a) Basis of Diagnosis

Table 4 demonstrates the proportion of cases that were morphologically verified (MV) using histology, cytology or bone marrow aspirate and trephine, diagnosed by clinical means or registered from death certificate-only information (DCO). Three thousand nine hundred sixty-nine of the registered 3978 cases had a method of diagnosis known.

Table 4: Percentage of cases Morphologically Verified (MV), diagnosed clinically or diagnosed by Death Certificate Only (DCO), EPBCR 2023

ICD 10 Cancer Site	Cases		Basis of Diagnosis		
	No. of Cases	% Total	DCO	Clinical	MV
C00 Lip	4	0,10	0.0	0.0	100.0
C02 Tongue	24	0,60	4.2	8.3	87.5
C03 Gum	1	0,03	0.0	0.0	100.0
C06 Mouth	32	0,81	0.0	6.2	93.8
C07 Salivary gland	9	0,23	0.0	0.0	100.0
C11 Naso-Oropharynx	30	0,76	0.0	9.7	87.1
C15 Oesophagus	102	2,57	12.7	12.7	74.5
C16 Stomach	62	1,56	0.0	1.6	96.8
C17 Small intestine	13	0,33	0.0	7.7	92.3
C18 Colorectal	271	6,83	1.5	9.6	88.9
C21 Anus	43	1,08	2.3	11.6	86.0
C22 Liver & Bile duct	88	2,22	3.4	25.0	71.6
C25 Pancreas	58	1,46	1.7	20.3	76.3
C32 Larynx	40	1,01	0.0	2.5	97.5
C34 Lung	135	3,40	8.8	10.9	78.8
C41 Bone	4	0,10	0.0	0.0	100.0
C43 Melanoma	72	1,81	0.0	1.4	98.6
C44 BCC	69	1,74	0.0	5.8	94.2
C44 SCC of Skin	59	1,49	0.0	0.0	100.0
C44 Skin other	35	0,88	0.0	8.6	91.4
C45 Mesothelioma	9	0,23	0.0	11.1	88.9
C46 Kaposi Sarcoma	28	0,71	3.6	21.4	75.0
C49 Connective tissue	23	0,58	0.0	4.3	95.7
C50 Breast	658	16,58	0.3	4.2	95.2
C51 Vulva	95	2,39	3.2	4.2	92.6
C52 Vagina	12	0,30	0.0	0.0	100.0
C53 Cervix	572	14,41	2.3	7.3	90.4
C54 Uterus	97	2,44	0.0	5.2	94.8
C56 Ovary	44	1,11	2.3	18.2	79.5

C58 Placenta	3	0,08	0.0	0.0	100.0
C60 Penis	20	0,50	0.0	10.0	90.0
C61 Prostate	637	16,05	1.1	13.2	85.7
C62 Testis	8	0,20	0.0	0.0	100.0
C63 Other specified	29	0,73	3.4	10.3	86.2
C64 Kidney	46	1,16	0.0	4.3	93.6
C67 Bladder	45	1,13	2.2	15.6	82.2
C69 Eye	13	0,33	0.0	0.0	100.0
C71 Brain, CNS	37	0,93	0.0	27.0	73.0
C73 Thyroid	21	0,53	0.0	14.3	85.7
C74 Endocrine	11	0,28	0.0	9.1	90.9
C76 Ill defined	16	0,40	0.0	0.0	100.0
C80 Primary site unknown	186	4,69	4.3	19.3	75.9
C81 Hodgkin lymphoma	31	0,78	0.0	6.5	93.5
C83 Burkitt lymphoma	3	0,08	0.0	0.0	100.0
C84 Non Hodgkin lymphoma	95	2,39	1.1	9.5	89.5
C90 Myeloma	28	0,71	0.0	3.6	96.4
C92 Leukaemia	37	0,93	0.0	5.4	94.6
C96 Haematology other	14	0,35	0.0	0.0	100.0
<b>All Sites</b>	<b>3,969</b>	<b>100</b>	<b>1.8</b>	<b>9.3</b>	<b>88.7</b>

#### **b) Primary site unknown (PSU)**

There were 187 cases of cancer (4.6%) reported where the primary site was unspecified or uncertain from the available documentation. The rates of PSU were 2.16 and 2.99 /100 000 in men and women, respectively.

#### **c) Age unknown**

There was 1 record with unknown age.



## **DISCUSSION**

This report marks the seventh year of cancer incidence report from the EPBCR, detailing cancer cases diagnosed during the year 2023. A total of 3,978 cancer cases were registered, with 1,659 (41.7%) in males and 2,319 (58.3%) in females. As in previous years, benign growths, in-situ lesions, and cancers of unknown behavior were excluded from the analysis.

The frequency and age-standardised incidence rates analysis of 2023 EPBCR show that the most common cancers among males were prostate, colorectal, lung, oesophageal, and non-Hodgkin lymphoma. For females, the leading cancers included breast, cervical, colorectal, uterine, and vulvar cancers. Notably, within the top five cancers, the White population exhibited the highest incidence rates across all categories, with the exception of cervical and vulvar cancers, where the Black population showed higher incidence rates. This disparity may reflect significant inequalities in access to healthcare services among different demographic groups. The majority of the White population has access to medical aid, which facilitates quicker access to diagnostic tests and treatment options. In contrast, many individuals in the Black population primarily rely on public healthcare services, which often face challenges such as limited resources and complicated referral system (12). These systemic barriers can lead to delays in diagnosis and treatment, ultimately impacting health outcomes for patients within these communities (13). The higher incidence of cervical cancer in the Black population underscores the increased vulnerability of Black women to this disease, largely due to the interplay of HPV (human papillomavirus) and HIV (human immunodeficiency virus) infections. HPV is a key risk factor for the development of cervical cancer, and high-risk strains of the virus are prevalent in South Africa (14,15).

Thirty-seven paediatric cancers were registered, accounting for 0.9% of all cancers, with 11 cases in boys and 26 in girls, and the most common types being neuroblastoma, CNS neoplasms, lymphoma, neuroblastoma, and retinoblastoma. Paediatric cancers continue to represent a small percentage of total cases, accounting for 0.9% in 2023, consistent with the 0.8% observed in 2022. This relatively stable proportion may stem from limitations in healthcare services, where facilities can only accommodate a finite number of patients seeking specialized care at any given time.

The overall percentage of morphologically verified cancer was 88.7% (ranging from 73% to 100%) with 11.3% cases being captured from clinical and death records, indicating the importance of a PBCR in capturing non-pathologically diagnosed cancers. The EPBCR's commitment to quality data collection is reflected in the high percentage of morphologically verified cases. This level of verification is crucial for ensuring accurate cancer statistics that can inform public health strategies. Notably, 4.6% of cases were reported with an unspecified primary site, which is an area for improvement in data collection practices.

In 2023, there was a 3% decrease in reported cancer cases, with 3,978 cases compared to 4,116 in 2022. Despite this reduction, the patterns of the most common cancers and their ASRs have remained stable from 2017 to 2023, indicating that while fewer cases were reported, the types of cancers in the population have not shifted significantly. This consistency suggests that the underlying risk factors and demographic characteristics contributing to cancer incidence remain unchanged. The ASR trend may be attributed to the extended use of the 2026 STATS SA denominator by the EPBCR. Recently, updated midyear population estimates revealed population growth from approximately 3 million to nearly 4 million, which may have impacted the observed incidence rates. Nonetheless, ASRs remain comparable globally, as we rely on a world population standard for standardization. Additionally, the NHLS hack in 2024 hindered cancer case finding, as the case mop-up was conducted in the second half of 2024, when the hack occurred. Furthermore, many cases that were followed remain unconfirmed due to a lack of access to laboratory results.

The KZN PBCR has published its first report for 2023 concurrently with this one, marking a significant step in the development of PBCRs in South Africa. The NCR is exploring the possibility of integrating the Eastern Cape Cancer Registry (ECCR) and providing technical support. This financial year, one cancer surveillance officer was assigned to the ECCR to aid in data collection at Nelson Mandela Academic Hospital. Additionally, discussions with the Western Cape Province commenced regarding the establishment of a third PBCR. The NCR will continue to implement additional PBCRs across South Africa, focusing on capacity building and fostering relationships with stakeholders. Collaboration with the private sector has also been strengthened, notably with the South African Oncology Consortium (SAOC) and Icon Oncology, to ensure comprehensive access to data from these sources to supplement private sector data. The EPBCR has incorporated data from both SAOC and Icon in its 2023

report, while the KZN PBCR is in discussions with SAOC to obtain future data. Furthermore, the NCR has been providing ongoing technical support to the KZN PBCR, including assistance with data collection techniques, management, and analysis. The EPBCR and KZN PBCR also presented their cancer registry data at the 2024 AFCRN meeting in Cape Town, where cancer registries from across Africa showcased their work and exchanged insights on new developments and cancer registration processes.

In summary, while the trends in cancer incidence in SA show stability, ongoing efforts to improve data quality are essential. By fostering collaboration with private and public sectors and expanding cancer registries, we can better understand and address the cancer burden in the population. This will ultimately inform effective healthcare policies and contribute to reducing cancer incidence and mortality rates in South Africa.

## **CONCLUSION**

In conclusion, the 2023 cancer incidence report from the EPBCR highlights both the stability and ongoing challenges within South Africa's cancer landscape, revealing a slight overall decrease in cases while maintaining consistent patterns in cancer types across demographics. The significant disparities in access to healthcare, particularly among the Black population, underscore the need for continued efforts to enhance data collection and verification, especially in the wake of disruptions like the NHLS hack. The hack limited access to lab results, preventing case confirmation through pathology reports, which are essential for entering data into REDCap, as lab reports were mailed directly to doctors and took longer to be filed. The collaborative initiatives to integrate and support regional cancer registries, along with partnerships with private sector organizations, are crucial for improving cancer surveillance and addressing gaps in care. As South Africa strives to refine its cancer control strategies, these efforts will be vital for better understanding the cancer burden and developing effective public health interventions aimed at reducing incidence and mortality rates.

## **ACKNOWLEDGEMENTS**

The NCR would also like to thank the National Institute for Communicable Diseases for the continuous support costs for EPBCR. The NCR would like to thank the National Department of Health for additional funding that has assisted in the continued operations of the EPBCR. The NCR would like to thank the SAMRC for seeding funding for this project. The NCR would like to also acknowledge Takeda Pharmaceutical Company Limited for supporting population-based cancer registration activities in EPBCR and the launch of the KZN population-based cancer registry.

The National Cancer Registry (NCR) would also like to thank all individuals, organisations and relevant stakeholders that played a critical role in the operations of the Ekurhuleni Population-Based Cancer Registry.

African Cancer Registry Network (AFCRN)

Ampath Laboratories

Arebaoke Hospice

Benoni Oncology Centre

Charlotte Maxeke Academic Hospital

Chris Hani Baragwanath Academic Hospital

Drs Gritzman & Thatcher Inc Laboratories

Eastrand Benoni Hospice

Edenvale Regional Hospital

Far East Regional Hospital

Gauteng Oncology Alberton Private Hospital

Gauteng Oncology Linmed Private Hospital

Gauteng Oncology Prostate-Clinic

Icon Oncology

International Agency for Research on Cancer (IARC)

International Association of Cancer Registries (IACR)

Lancet Laboratories

National Department of Health South Africa

National Health Laboratory Services

National Institute for Communicable Diseases

Pathcare Laboratories

Pholosong Regional Hospital

South African Medical Research Council (SAMRC)

South African Oncology Consortium (SAOC)

South African Paediatric Oncology Network

St Francis Hospice

Stepping Stone Hospice

Steve Biko Academic Hospital

Tambo Memorial Regional Hospital

Tembisa Regional Hospital

Thelle Mogoerane Regional Hospital

Union for International Cancer Control (UICC)

Vermaak Laboratories

World Health Organization (WHO)

## REFERENCES

1. International Agency for Research on Cancer. World Cancer report - Cancer research for cancer prevention. [Internet]. World Health Organization. 2020. p. 1–596. Available from: [https://www.iarc.who.int/cards\\_page/world-cancer-report/](https://www.iarc.who.int/cards_page/world-cancer-report/)
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*. 2024 May;74(3):229-63.
3. ICCP. Cancer Registries ICCP Portal. ICCP. 2019.
4. WHO. Cancer key facts. 2020.
5. Assembly UNG. Resolution A/RES/65/238: Scope, modalities, format and organization of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. 2011;11759(April):1–4.
6. IARC. The role and status of population-based cancer registration. 2007;X.
7. IARC. About the GICR. 2011.
8. Omonisi AE, Liu B, Parkin DM. Population-Based Cancer Registration in Sub-Saharan Africa: Its Role in Research and Cancer Control. *JCO Glob Oncol*. 2020 Nov;(6):1721–8.
9. KwaZulu-Natal Department of Health. Referral system: levels of care. 2014. p. 2017.
10. NHLS. 2017/18 NHLS Annual Report. Sandringham; 2018.
11. Parliament of the Republic of south Africa. Protection of Personal Information Act, 2013 Ensuring protection of your personal information and effective access to information. 2013;(4):154.
12. Lubuzo B, Ginindza T, Hlongwana K. Exploring barriers to lung cancer patient access, diagnosis, referral and treatment in Kwazulu-Natal, South Africa: the health providers' perspectives. *Transl Lung Cancer Res*. 2019;8(4):380.
13. Odiaka E, Lounsbury DW, Jalloh M, Adusei B, Diallo TA, Kane PMS, et al. Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). *J Glob Oncol*. 2018 Sep;4:1–12.

14. Singini MG, Singh E, Bradshaw D, Chen WC, Motlhale M, Kamiza AB, et al. HPV types 16/18 L1 E6 and E7 proteins seropositivity and cervical cancer risk in HIV-positive and HIV-negative black South African women. *Infect Agent Cancer*. 2022 Mar;17(1):14.
15. Chikandiwa A, Pisa PT, Sengayi M, Singh E, Delany-Moretlwe S. Patterns and trends of HPV-related cancers other than cervix in South Africa from 1994-2013. *Cancer Epidemiol*. 2019 Feb;58:121–9.

# **APPENDICES**

## Appendix 1: List of Data Sources

### **PUBLIC HOSPITALS**

- ❖ Charlotte Maxeke Johannesburg Academic Hospital
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Tshwane District Hospital
- ❖ Pholosong Regional Hospital
- ❖ Far East Rand Regional Hospital
- ❖ Thelle Mogoerane Regional Hospital
- ❖ Tembisa Regional Hospital
- ❖ Tambo Memorial Regional Hospital
- ❖ Edenvale Hospital

### **PRIVATE HEALTH FACILITIES**

- ❖ Benoni Oncology Centre
- ❖ Gauteng Prostate Oncology - Morehill Clinic
- ❖ Gauteng Oncology - Benoni Oncology Centre
- ❖ Gauteng Oncology - Linmed Hospital
- ❖ Netcare Clinton Oncology
- ❖ Independent Practitioners

### **HOSPICES**

- ❖ East Rand Hospice
- ❖ Flora Madiba Hospice
- ❖ Stepping Stone Hospice
- ❖ St Francis Hospice

### **SOUTH AFRICAN ONCOLOGY CONSORTIUM**

- ❖ Private Oncologists

### **ICON ONCOLOGY**



- ❖ Private Oncologists


### **PAEDIATRIC ONCOLOGY**

- ❖ CHOC Childhood cancer foundation
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Donald Gordon Medical Oncology Unit

### **NHLS**

- ❖ CDW pathology-based cancer reports

## Appendix 2: South African Cancer Notification Form

	<p><b>health</b> Department of Health REPUBLIC OF SOUTH AFRICA</p> <p><small>National Health Act, 2003 (Act No. 61 of 2003) Regulation Number 380</small></p>	<p>Republic of South Africa Department of Health</p> <p><b>CANCER REGISTRATION FORM</b></p>	<p>To be completed in duplicate in <b>BLOCK LETTERS</b>. Please mark with <input checked="" type="checkbox"/> the CORRECT box, where required. Original to be submitted to the National Cancer Register and copy to be retained: To be submitted to the National Cancer Register via: e-mail: cancer.registry@nhls.ac.za fax: 011 489 9132 / 011 489 9152 Post: P.O. Box 1038, Johannesburg, 2000.</p>
<b>A. PARTICULARS OF INDIVIDUAL</b>			
1. Name of facility <input type="text"/>			
USE PATIENT STICKER <i>if available</i>			
2. Surname <input type="text"/>			
3. Full names <input type="text"/>			
4. Date of birth <input type="text"/>			
5. Folder number <input type="text"/>			
6. Sex <input type="checkbox"/> Male <input type="checkbox"/> Female			
7. ID number/Passport number <input type="text"/>			
8. Race group <input type="checkbox"/> African <input type="checkbox"/> Coloured <input type="checkbox"/> White <input type="checkbox"/> Indian <input type="checkbox"/> Other _____			
9. Area of residence			
9.1 City/town/village <input type="text"/>			
9.2 Postal code <input type="text"/> 9.3 How long at this address? <input type="text"/> years			
Please record place of birth if not the same as current address			
9.4 City/town/village <input type="text"/>			
9.5 Postal code <input type="text"/>			
<b>B. RISK FACTOR PROFILE</b>			
10. Usual occupation of patient <input type="text"/> (If retired, give type of work done for most of working life)			
11. Type of industry/business <input type="text"/> (e.g. Mining, farming etc)			
12. Did the patient ever smoke tobacco? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown			
13. Did the patient ever consume alcohol regularly? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown (that is, more than once a week)			
14. HIV status <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Unknown			
<b>C. CLINICAL AND LABORATORY DETAILS</b>			
15. Date of diagnosis <input type="text"/>			
16. Cancer diagnosis and Histology <input type="text"/> 17. ICD-10 <input type="text"/> • <input type="text"/>			
<i>Please give all information available on the site, laterality, histology and behaviour of the tumour</i>			
18. Grade <input type="checkbox"/> Well differentiated <input type="checkbox"/> Moderately differentiated <input type="checkbox"/> Poorly differentiated <input type="checkbox"/> Unknown/Not applicable			
19. Stage <input type="checkbox"/> Primary/localised <input type="checkbox"/> Metastatic <input type="checkbox"/> Unknown/Not applicable			
20. Invasiveness <input type="checkbox"/> In-situ <input type="checkbox"/> Invasive			
21. Basis of diagnosis <input type="checkbox"/> Clinical <input type="checkbox"/> Clinical with investigation <input type="checkbox"/> Cytology/histopathology <input type="checkbox"/> Molecular <input type="checkbox"/> Death Certificate			
22. Prescribed treatment <input type="checkbox"/> Surgery <input type="checkbox"/> Radiation <input type="checkbox"/> Chemotherapy <input type="checkbox"/> Other <input type="checkbox"/> Palliation <input type="checkbox"/> Alternative <input type="checkbox"/> None			
<p><b>INFORMANT PARTICULARS</b></p> <p>Name (Print) _____</p> <p>MP/NC Number <input type="text"/></p> <p>Signature _____ Date _____</p>			<p><b>OFFICE CODING</b></p> <p><input type="text"/> • <input type="text"/></p> <p>M - <input type="text"/> / <input type="text"/> / <input type="text"/></p>

Appendix 3: Tables of Incidence by site, sex, age group and population, 2023

**Tables of ASR and Crude Incidence by population group**

<b>Asian Females: Crude and Age-Adjusted Incidence Rates/100 000</b>							
<b>Site</b>	<b>N (Obs)</b>	<b>N (Obs) Percent</b>	<b>N(Adj)</b>	<b>Crude Incidence</b>	<b>ASR</b>	<b>ASR 95% LCL</b>	<b>ASR 95% UCL</b>
Breast	16	41,03	16	16,90	11,12	6,34	18,93
Colorectal	4	10,26	4	4,23	2,95	0,80	8,64
Uterus	4	10,26	4	4,23	2,95	0,80	8,64
Connective tissue	3	7,69	3	3,17	2,11	0,43	7,46
Stomach	2	5,13	2	2,11	1,50	0,18	6,68
Lung	2	5,13	2	2,11	1,38	0,17	6,43
Hodgkin lymphoma	1	2,56	1	1,06	1,52	0,04	7,66
Myeloma	1	2,56	1	1,06	0,77	0,02	5,67
Primary site unknown	1	2,56	1	1,06	0,76	0,02	5,64
Mesothelioma	1	2,56	1	1,06	0,69	0,02	5,49
Pancreas	1	2,56	1	1,06	0,69	0,02	5,49
Thyroid	1	2,56	1	1,06	0,68	0,02	5,48
Cervix	1	2,56	1	1,06	0,65	0,02	5,41
Vulva	1	2,56	1	1,06	0,53	0,01	5,19
<b>All sites</b>	<b>39</b>	<b>100</b>	<b>39</b>	<b>41,23</b>	<b>28,30</b>	<b>8,89</b>	<b>102,81</b>

<b>Black Females: Crude and Age-Adjusted Incidence Rates/100 000</b>							
<b>Site</b>	<b>N (Obs)</b>	<b>N (Obs) Percent</b>	<b>N(Adj)</b>	<b>Crude Incidence</b>	<b>ASR</b>	<b>ASR 95% LCL</b>	<b>ASR 95% UCL</b>
Cervix	524	34,05	524	16,97	18,04	16,46	19,74
Breast	348	22,61	348	11,27	11,87	10,57	13,27
Vulva	84	5,46	84	2,72	2,52	1,99	3,15
Uterus	74	4,81	74	2,40	3,31	2,57	4,17
Colorectal	72	4,68	72	2,33	2,76	2,14	3,50
Primary site unknown	71	4,61	71	2,30	2,52	1,95	3,21
Oesophagus	31	2,01	31	1,00	1,22	0,82	1,73
Ovary	25	1,62	25	0,81	0,95	0,60	1,42
Anus	22	1,43	22	0,71	0,64	0,39	1,00
Lung	21	1,36	21	0,68	0,92	0,56	1,42
Non Hodgkin lymphoma	21	1,36	21	0,68	0,71	0,43	1,11
Liver & Bile duct	20	1,30	20	0,65	0,82	0,49	1,28
SCC of Skin	15	0,97	15	0,49	0,44	0,24	0,74
Stomach	13	0,84	13	0,42	0,54	0,28	0,93
Leukaemia	12	0,78	12	0,39	0,53	0,26	0,95
Other specified	12	0,78	12	0,39	0,40	0,20	0,72
Kidney	11	0,71	11	0,36	0,40	0,20	0,72
Hodgkin lymphoma	11	0,71	11	0,36	0,39	0,19	0,71
Thyroid	11	0,71	11	0,36	0,32	0,16	0,60
Vagina	10	0,65	10	0,32	0,41	0,19	0,77
Skin other	9	0,58	9	0,29	0,41	0,17	0,79
Brain, CNS	9	0,58	9	0,29	0,39	0,17	0,76
Ill defined	9	0,58	9	0,29	0,37	0,16	0,72
Bladder	9	0,58	9	0,29	0,35	0,16	0,67
Pancreas	9	0,58	9	0,29	0,32	0,14	0,61
Naso-Oropharynx	9	0,58	9	0,29	0,31	0,14	0,61
Kaposi Sarcoma	9	0,58	9	0,29	0,22	0,10	0,45
Myeloma	7	0,45	7	0,23	0,28	0,10	0,60
Mouth	7	0,45	7	0,23	0,26	0,10	0,55
Melanoma	7	0,45	7	0,23	0,26	0,10	0,54
BCC	7	0,45	7	0,23	0,21	0,08	0,44
Eye	6	0,39	6	0,19	0,20	0,07	0,46
Tongue	6	0,39	6	0,19	0,17	0,06	0,40
Connective tissue	5	0,32	5	0,16	0,18	0,06	0,43
Larynx	4	0,26	4	0,13	0,14	0,04	0,37
Haematology other	3	0,19	3	0,10	0,12	0,02	0,34
Small intestine	3	0,19	3	0,10	0,11	0,02	0,33
Salivary gland	3	0,19	3	0,10	0,09	0,02	0,30
Placenta	3	0,19	3	0,10	0,09	0,02	0,28
Endocrine	3	0,19	3	0,10	0,09	0,02	0,28
Lip	2	0,13	2	0,06	0,05	0,01	0,23
Mesothelioma	1	0,06	1	0,03	0,04	0,00	0,23
Burkitt lymphoma	1	0,06	1	0,03	0,04	0,00	0,22
<b>All sites</b>	<b>1539</b>	<b>100</b>	<b>1539</b>	<b>49,85</b>	<b>54,41</b>	<b>42,45</b>	<b>71,75</b>

Coloured Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	15	31,25	15	4,65	3,99	2,20	6,72
Cervix	12	25,00	12	3,72	3,13	1,61	5,58
Primary site unknown	3	6,25	3	0,93	0,98	0,19	2,87
Vulva	3	6,25	3	0,93	0,72	0,15	2,29
Hodgkin lymphoma	1	2,08	1	0,31	0,31	0,01	1,75
Bladder	1	2,08	1	0,31	0,30	0,01	1,72
SCC of Skin	1	2,08	1	0,31	0,28	0,01	1,69
Stomach	1	2,08	1	0,31	0,28	0,01	1,69
BCC	1	2,08	1	0,31	0,28	0,01	1,69
Mouth	1	2,08	1	0,31	0,28	0,01	1,69
Vagina	1	2,08	1	0,31	0,27	0,01	1,66
Uterus	1	2,08	1	0,31	0,27	0,01	1,66
Oesophagus	1	2,08	1	0,31	0,26	0,01	1,62
Colorectal	1	2,08	1	0,31	0,25	0,01	1,61
Skin other	1	2,08	1	0,31	0,25	0,01	1,61
Tongue	1	2,08	1	0,31	0,25	0,01	1,61
Kaposi Sarcoma	1	2,08	1	0,31	0,24	0,01	1,59
Ovary	1	2,08	1	0,31	0,22	0,01	1,53
Liver & Bile duct	1	2,08	1	0,31	0,22	0,01	1,53
<b>All sites</b>	<b>48</b>	<b>100</b>	<b>48</b>	<b>14,88</b>	<b>12,78</b>	<b>4,30</b>	<b>42,11</b>

White Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	266	39,12	266	98,14	53,85	47,16	61,44
Colorectal	57	8,38	57	21,03	10,53	7,86	14,16
Cervix	33	4,85	33	12,18	7,94	5,41	11,53
Primary site unknown	31	4,56	31	11,44	7,27	4,26	11,63
Melanoma	29	4,26	29	10,70	5,55	3,48	8,72
Lung	25	3,68	25	9,22	4,63	2,24	8,43
BCC	24	3,53	24	8,85	4,63	2,65	7,78
Liver & Bile duct	22	3,24	22	8,12	3,66	2,23	6,16
Pancreas	19	2,79	19	7,01	3,50	2,05	6,01
Uterus	18	2,65	18	6,64	3,59	2,07	6,20
Ovary	18	2,65	18	6,64	3,37	1,94	5,89
Brain, CNS	12	1,76	12	4,43	2,72	1,39	5,20
Non Hodgkin lymphoma	12	1,76	12	4,43	2,39	1,21	4,72
SCC of Skin	12	1,76	12	4,43	1,54	0,78	3,45
Mouth	10	1,47	10	3,69	2,21	0,95	4,70
Leukaemia	9	1,32	9	3,32	1,88	0,75	4,27
Bladder	9	1,32	9	3,32	1,40	0,62	3,38
Stomach	7	1,03	7	2,58	1,48	0,58	3,62
Vulva	7	1,03	7	2,58	1,43	0,54	3,57
Skin other	7	1,03	7	2,58	1,37	0,50	3,50
Kidney	7	1,03	7	2,58	1,33	0,49	3,42
Myeloma	6	0,88	6	2,21	2,18	0,40	5,98
Thyroid	5	0,74	5	1,84	1,15	0,28	3,44
Tongue	4	0,59	4	1,48	1,15	0,23	3,56
Other specified	4	0,59	4	1,48	0,75	0,17	2,71
Anus	4	0,59	4	1,48	0,69	0,18	2,57
Small intestine	4	0,59	4	1,48	0,60	0,15	2,42
Haematology other	4	0,59	4	1,48	0,55	0,14	2,34
Endocrine	3	0,44	3	1,11	0,64	0,13	2,55
Eye	2	0,29	2	0,74	0,37	0,04	2,19
Naso-Oropharynx	2	0,29	2	0,74	0,34	0,03	2,15
Oesophagus	2	0,29	2	0,74	0,21	0,02	1,95
Vagina	1	0,15	1	0,37	0,23	0,01	2,05
Bone	1	0,15	1	0,37	0,21	0,01	2,02
Larynx	1	0,15	1	0,37	0,18	0,00	1,96
Connective tissue	1	0,15	1	0,37	0,18	0,00	1,96
Lip	1	0,15	1	0,37	0,18	0,00	1,96
Hodgkin lymphoma	1	0,15	1	0,37	0,09	0,00	1,84
<b>All sites</b>	<b>680</b>	<b>100</b>	<b>680</b>	<b>251</b>	<b>135,97</b>	<b>90,95</b>	<b>231,43</b>

Asian Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	8	25,00	8	6,96	5,78	2,49	12,17
Colorectal	4	12,50	4	3,48	2,57	0,68	7,79
Non Hodgkin lymphoma	3	9,38	3	2,61	2,05	0,40	7,19
Stomach	3	9,38	3	2,61	1,60	0,33	6,30
Pancreas	2	6,25	2	1,74	1,31	0,16	6,10
Lung	2	6,25	2	1,74	1,30	0,15	6,07
Brain, CNS	1	3,13	1	0,87	1,57	0,04	7,63
Bone	1	3,13	1	0,87	1,23	0,03	6,63
Leukaemia	1	3,13	1	0,87	0,75	0,02	5,40
SCC of Skin	1	3,13	1	0,87	0,73	0,02	5,37
Endocrine	1	3,13	1	0,87	0,67	0,02	5,23
Primary site unknown	1	3,13	1	0,87	0,58	0,01	5,05
Hodgkin lymphoma	1	3,13	1	0,87	0,58	0,01	5,05
Anus	1	3,13	1	0,87	0,57	0,01	5,03
Kidney	1	3,13	1	0,87	0,57	0,01	5,03
Testis	1	3,13	1	0,87	0,49	0,01	4,89
<b>All sites</b>	<b>32</b>	<b>100</b>	<b>32</b>	<b>27,84</b>	<b>22,35</b>	<b>4,39</b>	<b>100,93</b>

Black Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	352	39,55	352	10,65	17,80	15,76	20,00
Colorectal	66	7,42	66	2,00	2,54	1,91	3,31
Lung	52	5,84	52	1,57	2,05	1,52	2,72
Oesophagus	50	5,62	50	1,51	2,08	1,54	2,76
Primary site unknown	43	4,83	43	1,30	1,49	1,05	2,05
Non Hodgkin lymphoma	37	4,16	37	1,12	1,27	0,83	1,85
Liver & Bile duct	27	3,03	27	0,82	1,08	0,70	1,59
Larynx	24	2,70	24	0,73	0,90	0,57	1,36
Stomach	21	2,36	21	0,64	0,78	0,47	1,23
Penis	19	2,13	19	0,57	0,67	0,40	1,06
Naso-Oropharynx	16	1,80	16	0,48	0,64	0,36	1,05
Kaposi Sarcoma	16	1,80	16	0,48	0,48	0,26	0,82
Anus	14	1,57	14	0,42	0,42	0,22	0,75
Myeloma	11	1,24	11	0,33	0,38	0,18	0,70
Kidney	10	1,12	10	0,30	0,44	0,21	0,81
Other specified	10	1,12	10	0,30	0,37	0,17	0,71
Tongue	9	1,01	9	0,27	0,35	0,15	0,69
Brain, CNS	9	1,01	9	0,27	0,29	0,13	0,58
Skin other	9	1,01	9	0,27	0,25	0,11	0,53
Hodgkin lymphoma	9	1,01	9	0,27	0,23	0,10	0,50
Pancreas	8	0,90	8	0,24	0,30	0,12	0,62
Bladder	8	0,90	8	0,24	0,28	0,11	0,58
SCC of Skin	8	0,90	8	0,24	0,26	0,10	0,55
Leukaemia	8	0,90	8	0,24	0,23	0,09	0,49
Connective tissue	8	0,90	8	0,24	0,22	0,09	0,49
Breast	7	0,79	7	0,21	0,51	0,16	1,11
Mouth	7	0,79	7	0,21	0,39	0,12	0,88
Ill defined	6	0,67	6	0,18	0,22	0,08	0,51
Eye	5	0,56	5	0,15	0,17	0,05	0,43
Small intestine	5	0,56	5	0,15	0,16	0,05	0,42
Melanoma	3	0,34	3	0,09	0,12	0,02	0,37
Salivary gland	3	0,34	3	0,09	0,09	0,02	0,32
Testis	2	0,22	2	0,06	0,07	0,01	0,28
BCC	2	0,22	2	0,06	0,06	0,01	0,27
Burkitt lymphoma	1	0,11	1	0,03	0,03	0,00	0,23
Haematology other	1	0,11	1	0,03	0,03	0,00	0,23
Bone	1	0,11	1	0,03	0,03	0,00	0,23
Lip	1	0,11	1	0,03	0,02	0,00	0,21
Endocrine	1	0,11	1	0,03	0,02	0,00	0,21
Thyroid	1	0,11	1	0,03	0,02	0,00	0,20
<b>All sites</b>	<b>890</b>	<b>100</b>	<b>890</b>	<b>26,88</b>	<b>37,74</b>	<b>27,67</b>	<b>53,70</b>



Coloured Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	9	32,14	9	2,59	2,34	1,06	4,61
Non Hodgkin lymphoma	6	21,43	6	1,73	2,18	0,63	5,11
Lung	5	17,86	5	1,44	1,29	0,41	3,21
Colorectal	3	10,71	3	0,86	0,66	0,14	2,25
Liver & Bile duct	1	3,57	1	0,29	0,33	0,01	1,91
Leukaemia	1	3,57	1	0,29	0,29	0,01	1,79
Primary site unknown	1	3,57	1	0,29	0,29	0,01	1,79
Bladder	1	3,57	1	0,29	0,25	0,01	1,70
Kaposi Sarcoma	1	3,57	1	0,29	0,19	0,00	1,55
<b>All sites</b>	<b>28</b>	<b>100</b>	<b>28</b>	<b>8</b>	<b>7,82</b>	<b>2,28</b>	<b>23,92</b>

White Males: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	265	37,86	265	87,09	38,21	33,59	43,57
Colorectal	64	9,14	64	21,03	10,92	8,32	14,38
BCC	35	5,00	35	11,50	4,92	3,39	7,34
Primary site unknown	34	4,86	34	11,17	7,17	4,25	11,34
Melanoma	33	4,71	33	10,85	5,48	3,71	8,19
Lung	28	4,00	28	9,20	3,97	2,57	6,31
SCC of Skin	22	3,14	22	7,23	2,87	1,76	4,95
Oesophagus	18	2,57	18	5,92	2,79	1,60	4,99
Pancreas	18	2,57	18	5,92	2,75	1,59	4,91
Liver & Bile duct	17	2,43	17	5,59	2,47	1,40	4,54
Stomach	16	2,29	16	5,26	2,67	1,42	4,98
Bladder	16	2,29	16	5,26	2,48	1,40	4,59
Kidney	16	2,29	16	5,26	2,42	1,36	4,50
Non Hodgkin lymphoma	15	2,14	15	4,93	2,79	1,39	5,30
Larynx	11	1,57	11	3,62	1,39	0,68	3,20
Skin other	9	1,29	9	2,96	1,56	0,60	3,69
Hodgkin lymphoma	7	1,00	7	2,30	2,32	0,83	5,15
Mouth	7	1,00	7	2,30	1,28	0,51	3,21
Mesothelioma	7	1,00	7	2,30	0,95	0,38	2,69
Haematology other	6	0,86	6	1,97	1,19	0,30	3,39
Brain, CNS	6	0,86	6	1,97	1,14	0,40	3,07
Leukaemia	6	0,86	6	1,97	1,01	0,34	2,88
Connective tissue	6	0,86	6	1,97	1,00	0,36	2,83
Testis	5	0,71	5	1,64	1,81	0,55	4,44
Breast	5	0,71	5	1,64	0,70	0,22	2,42
Tongue	4	0,57	4	1,31	0,70	0,19	2,48
Naso-Oropharynx	4	0,57	4	1,31	0,44	0,11	2,09
Thyroid	3	0,43	3	0,99	0,52	0,11	2,26
Salivary gland	3	0,43	3	0,99	0,36	0,07	2,02
Endocrine	2	0,29	2	0,66	0,54	0,06	2,41
Anus	2	0,29	2	0,66	0,44	0,05	2,23
Myeloma	2	0,29	2	0,66	0,30	0,03	1,98
Other specified	2	0,29	2	0,66	0,29	0,03	1,96
Penis	1	0,14	1	0,33	0,26	0,01	2,01
Bone	1	0,14	1	0,33	0,18	0,00	1,86
Gum	1	0,14	1	0,33	0,18	0,00	1,86
Burkitt lymphoma	1	0,14	1	0,33	0,17	0,00	1,84
Kaposi Sarcoma	1	0,14	1	0,33	0,13	0,00	1,78
Ill defined	1	0,14	1	0,33	0,08	0,00	1,72
<b>All sites</b>	<b>700</b>	<b>100</b>	<b>700</b>	<b>230,07</b>	<b>110,85</b>	<b>73,58</b>	<b>195,36</b>

**Age-Specific Incidence Rates /100 000 and Lifetime Risk reported as 1: x**

ALL FEMALES																		
Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	9,60	4,32	4,95	3,33	9,44	21,68	44,19	86,68	165,38	188,78	266,32	313,67	406,52	403,97	633,26	766,81	1387,88	8
All sites but C44	9,60	4,32	3,71	3,33	8,76	21,12	43,71	84,74	158,08	187,26	260,60	306,23	400,31	393,45	598,95	710,42	1239,18	9
Anus	0,00	0,00	0,00	0,00	0,00	0,00	1,43	1,94	2,43	4,57	2,86	0,00	1,55	2,10	3,12	11,28	12,39	1001
BCC	0,00	0,00	0,62	0,00	0,67	0,56	0,00	0,00	2,43	0,76	2,86	3,72	1,55	6,31	15,60	22,55	61,96	571
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,61	2,28	0,00	1,24	4,65	12,62	6,24	11,28	24,78	724
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,55	0,00	0,00	0,00	0,00	12904
Brain, CNS	1,80	0,62	0,62	0,00	0,00	0,00	0,00	0,00	0,61	2,28	4,77	2,48	1,55	4,21	3,12	0,00	12,39	907
Breast	0,00	0,00	0,00	0,00	3,37	4,45	10,93	33,90	45,60	51,76	72,55	92,99	103,96	128,34	171,57	186,06	396,54	28
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,95	0,00	0,00	0,00	0,00	0,00	0,00	21053
Cervix	0,00	0,00	0,00	0,00	0,00	2,22	16,15	27,12	57,15	76,12	73,50	83,07	80,68	67,33	90,47	84,57	148,70	35
Colorectal	0,00	0,00	0,00	0,67	0,00	0,56	0,48	3,39	6,08	6,85	13,36	14,88	37,24	42,08	49,91	78,94	61,96	114
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,48	0,61	0,00	0,00	1,24	3,10	2,10	3,12	5,64	0,00	1785
Endocrine	0,00	0,00	0,62	0,00	0,00	0,00	0,00	0,97	0,00	0,76	0,95	1,24	1,55	0,00	0,00	0,00	0,00	3285
Eye	0,60	0,00	0,62	0,00	0,00	0,00	0,00	0,00	1,22	0,76	0,95	0,00	1,55	0,00	3,12	0,00	0,00	2268
Haematology other	0,00	0,62	0,00	0,67	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,10	6,24	0,00	24,78	2077
Hodgkin lymphoma	0,00	0,62	0,00	0,00	1,35	1,11	0,00	0,00	0,61	0,76	3,82	2,48	0,00	0,00	0,00	5,64	0,00	1861
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,61	0,76	2,86	0,00	1,55	0,00	3,12	0,00	12,39	2133
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	1,11	0,95	0,97	1,82	0,76	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3566
Kidney	0,60	1,85	0,00	0,00	0,67	0,00	0,00	0,00	2,43	0,76	1,91	1,24	1,55	4,21	3,12	11,28	0,00	1091
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,00	0,00	0,95	1,24	0,00	2,10	3,12	0,00	0,00	2535
Leukaemia	1,80	0,00	0,00	0,00	0,00	1,11	0,48	0,00	0,00	0,76	0,00	3,72	3,10	4,21	3,12	16,91	37,18	1093
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,00	0,00	0,76	0,00	0,00	0,00	2,10	0,00	0,00	0,00	5989
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,61	0,76	8,59	11,16	1,55	8,42	21,84	39,47	37,18	375
Lung	0,60	0,00	0,62	0,00	0,00	0,00	0,00	0,00	0,61	1,52	1,91	6,20	7,76	12,62	24,96	67,66	74,35	353

Melanoma	0,00	0,00	0,62	0,00	0,67	0,56	0,00	0,97	0,00	0,76	0,95	6,20	7,76	10,52	18,72	28,19	37,18	420
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,24	0,00	0,00	3206
Mouth	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,48	0,00	0,76	1,91	3,72	6,21	4,21	9,36	5,64	0,00	736
Myeloma	0,60	0,00	0,00	0,00	0,00	0,56	0,48	0,00	0,61	0,00	1,91	1,24	4,65	4,21	0,00	5,64	12,39	1403
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,61	2,28	2,86	0,00	3,10	0,00	0,00	0,00	12,39	2144
Non Hodgkin lymphoma	0,60	0,00	0,00	0,00	0,00	1,67	1,43	0,48	1,22	1,52	3,82	4,96	12,41	6,31	3,12	5,64	0,00	533
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,00	0,00	3,81	2,86	6,20	7,76	10,52	6,24	39,47	12,39	529
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,48	2,43	1,52	1,91	1,24	1,55	6,31	0,00	0,00	24,78	1257
Ovary	0,00	0,00	0,00	0,00	0,00	0,56	0,48	1,45	1,82	0,76	2,86	12,40	9,31	12,62	18,72	16,91	12,39	328
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,48	0,48	1,22	0,76	3,82	6,20	4,65	6,31	12,48	16,91	37,18	550
Placenta	0,00	0,00	0,00	0,00	0,67	0,56	0,00	0,00	0,61	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10870
Primary site unknown	3,00	0,62	0,62	2,00	0,00	1,67	2,85	2,91	4,86	6,85	10,50	18,60	24,83	12,62	31,20	0,00	86,74	163
SCC of Skin	0,00	0,00	0,00	0,00	0,00	0,00	0,48	1,45	3,04	0,00	0,95	2,48	3,10	0,00	15,60	22,55	61,96	739
Salivary gland	0,00	0,00	0,00	0,00	0,67	0,00	0,00	0,48	0,00	0,00	0,95	0,00	0,00	0,00	0,00	0,00	0,00	9524
Skin other	0,00	0,00	0,62	0,00	0,00	0,00	0,00	0,48	1,82	0,76	1,91	1,24	1,55	4,21	3,12	11,28	24,78	1274
Small intestine	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,00	0,00	1,91	0,00	1,55	0,00	3,12	0,00	24,78	2802
Stomach	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,61	3,04	3,82	1,24	9,31	2,10	9,36	0,00	24,78	666
Thyroid	0,00	0,00	0,00	0,00	0,00	1,67	0,95	0,97	1,22	0,76	2,86	1,24	1,55	0,00	0,00	5,64	12,39	1783
Tongue	0,00	0,00	0,00	0,00	0,67	0,00	0,48	0,48	1,22	0,00	1,91	0,00	4,65	0,00	3,12	0,00	0,00	1597
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,97	3,04	3,81	6,68	9,92	34,14	21,04	74,87	45,11	74,35	130
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,22	0,76	4,77	0,00	4,65	0,00	0,00	0,00	12,39	1755
Vulva	0,00	0,00	0,00	0,00	0,67	1,11	4,75	3,87	16,42	7,61	14,32	9,92	9,31	2,10	6,24	22,55	12,39	263

ASIAN FEMALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	0,00	0,00	38,03	0,00	22,79	40,87	107,83	0,00	151,74	240,82	202,95	205,21	481,86	213,18	0,00	14
All sites but C44	0,00	0,00	0,00	0,00	38,03	0,00	22,79	40,87	107,83	0,00	151,74	240,82	202,95	205,21	481,86	213,18	0,00	14
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,44	86,27	0,00	60,69	68,81	40,59	153,91	137,67	106,59	0,00	36
Cervix	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	21,57	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	928
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30,35	0,00	40,59	0,00	137,67	0,00	0,00	96
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,44	0,00	0,00	0,00	34,40	40,59	0,00	0,00	0,00	0,00	210
Hodgkin lymphoma	0,00	0,00	0,00	0,00	38,03	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	526
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	68,81	0,00	0,00	0,00	0,00	0,00	291
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	68,84	0,00	0,00	291
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	51,30	0,00	0,00	0,00	390
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	34,40	0,00	0,00	0,00	0,00	0,00	582
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30,35	0,00	0,00	0,00	0,00	0,00	0,00	659
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	40,59	0,00	68,84	0,00	0,00	183
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	22,79	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	878
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30,35	34,40	40,59	0,00	68,84	0,00	0,00	115
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	106,59	0,00	

**BLACK FEMALES**

Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	8,44	4,45	5,17	3,24	7,94	22,25	52,52	98,18	186,73	231,44	280,57	312,85	356,61	288,77	455,61	422,79	724,23	9
All sites but C44	8,44	4,45	4,43	3,24	7,94	21,51	51,89	95,61	178,39	231,44	275,91	305,49	352,18	285,82	455,61	407,41	691,31	9
Anus	0,00	0,00	0,00	0,00	0,00	0,00	1,90	2,57	3,33	6,94	3,10	0,00	0,00	2,95	0,00	15,37	0,00	963
BCC	0,00	0,00	0,00	0,00	0,00	0,74	0,00	0,00	3,33	0,00	1,55	1,84	0,00	0,00	0,00	0,00	0,00	2681
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,83	2,31	0,00	1,84	4,43	5,89	4,47	0,00	0,00	1012
Brain, CNS	2,11	0,74	0,74	0,00	0,00	0,00	0,00	0,00	0,00	1,16	0,00	1,84	0,00	2,95	0,00	0,00	16,46	2097
Breast	0,00	0,00	0,00	0,00	3,53	2,97	10,76	36,58	44,18	55,55	58,90	71,77	64,23	64,82	89,34	46,12	181,06	40
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,55	0,00	0,00	0,00	0,00	0,00	0,00	12904
Cervix	0,00	0,00	0,00	0,00	0,00	2,97	21,51	33,37	68,35	104,15	100,76	119,62	110,75	85,45	125,07	107,62	181,06	26
Colorectal	0,00	0,00	0,00	0,81	0,00	0,74	0,63	3,21	7,50	4,63	7,75	14,72	33,22	29,47	22,33	46,12	32,92	160
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,74	0,00	0,00	0,83	0,00	0,00	0,00	2,21	0,00	4,47	7,69	0,00	2425
Endocrine	0,00	0,00	0,74	0,00	0,00	0,00	0,00	0,64	0,00	1,16	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7875
Eye	0,70	0,00	0,74	0,00	0,00	0,00	0,00	0,00	1,67	1,16	0,00	0,00	2,21	0,00	0,00	0,00	0,00	3087
Haematology other	0,00	0,74	0,00	0,81	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4,47	0,00	0,00	3323
Hodgkin lymphoma	0,00	0,74	0,00	0,00	0,88	0,74	0,00	0,00	0,83	1,16	6,20	3,68	0,00	0,00	0,00	0,00	0,00	1406
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,83	1,16	4,65	0,00	2,21	0,00	4,47	0,00	16,46	1433
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	1,48	1,27	1,28	1,67	1,16	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2916
Kidney	0,00	2,22	0,00	0,00	0,88	0,00	0,00	0,00	1,67	1,16	3,10	0,00	2,21	0,00	4,47	0,00	0,00	1274
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,00	0,00	1,55	1,84	0,00	0,00	4,47	0,00	0,00	2353
Leukaemia	2,11	0,00	0,00	0,00	0,00	0,74	0,63	0,00	0,00	1,16	0,00	1,84	0,00	2,95	0,00	15,37	32,92	2121
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,63	0,00	0,00	1,16	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11174
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,83	0,00	6,20	7,36	2,21	5,89	22,33	7,69	16,46	440
Lung	0,00	0,00	0,74	0,00	0,00	0,00	0,00	0,00	0,83	2,31	1,55	1,84	6,64	5,89	17,87	30,75	32,92	531
Melanoma	0,00	0,00	0,74	0,00	0,00	0,00	0,00	0,64	0,00	1,16	0,00	1,84	2,21	0,00	8,93	0,00	0,00	1289
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4,47	0,00	0,00	4475

Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,00	0,00	1,55	3,68	4,43	2,95	0,00	0,00	0,00	1510
Myeloma	0,00	0,00	0,00	0,00	0,00	0,74	0,63	0,00	0,83	0,00	1,55	1,84	2,21	0,00	0,00	0,00	16,46	2565
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,83	3,47	3,10	0,00	4,43	0,00	0,00	0,00	0,00	1604
Non Hodgkin lymphoma	0,70	0,00	0,00	0,00	0,00	2,23	1,90	0,64	0,83	2,31	3,10	5,52	8,86	2,95	0,00	0,00	0,00	689
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,63	0,00	0,00	5,79	4,65	9,20	11,07	14,73	8,93	38,44	0,00	364
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,64	3,33	1,16	3,10	1,84	2,21	5,89	0,00	0,00	0,00	1101
Ovary	0,00	0,00	0,00	0,00	0,00	0,74	0,00	1,93	1,67	1,16	4,65	9,20	6,64	8,84	8,93	7,69	16,46	458
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,63	0,00	1,67	0,00	0,00	1,84	2,21	2,95	4,47	15,37	0,00	1453
Placenta	0,00	0,00	0,00	0,00	0,88	0,74	0,00	0,00	0,83	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8164
Primary site unknown	2,81	0,00	0,74	1,62	0,00	2,23	3,80	3,21	5,84	5,79	12,40	20,24	22,15	8,84	22,33	0,00	16,46	179
SCC of Skin	0,00	0,00	0,00	0,00	0,00	0,00	0,63	1,93	4,17	0,00	1,55	3,68	2,21	0,00	0,00	15,37	0,00	1412
Salivary gland	0,00	0,00	0,00	0,00	0,88	0,00	0,00	0,64	0,00	0,00	1,55	0,00	0,00	0,00	0,00	0,00	0,00	6515
Skin other	0,00	0,00	0,74	0,00	0,00	0,00	0,00	0,64	0,83	0,00	1,55	1,84	2,21	2,95	0,00	0,00	32,92	1859
Small intestine	0,00	0,00	0,00	0,00	0,00	0,74	0,00	0,00	0,00	0,00	1,55	0,00	2,21	0,00	0,00	0,00	0,00	4445
Stomach	0,00	0,00	0,00	0,00	0,00	0,74	0,00	0,00	0,00	4,63	4,65	1,84	2,21	2,95	4,47	0,00	16,46	931
Thyroid	0,00	0,00	0,00	0,00	0,00	1,48	0,63	1,28	1,67	1,16	3,10	0,00	2,21	0,00	0,00	0,00	0,00	1735
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,63	0,64	1,67	0,00	1,55	0,00	2,21	0,00	0,00	0,00	0,00	2986
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,50	5,79	7,75	9,20	33,22	29,47	84,87	46,12	98,76	116
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,67	1,16	6,20	0,00	4,43	0,00	0,00	0,00	16,46	1486
Vulva	0,00	0,00	0,00	0,00	0,88	1,48	5,69	5,13	21,67	11,57	20,15	12,88	8,86	0,00	4,47	23,06	0,00	216

COLOURED FEMALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	8,48	0,00	0,00	0,00	7,63	0,00	0,00	73,14	69,28	122,14	77,15	40,93	18,70	113,09	102,26	91,88	38
All sites but C44	0,00	8,48	0,00	0,00	0,00	7,63	0,00	0,00	73,14	69,28	111,96	77,15	40,93	18,70	56,55	102,26	91,88	44
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	28,27	0,00	0,00	708
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,90	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2021
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	32,51	19,79	30,53	33,06	0,00	18,70	0,00	51,13	91,88	149
Cervix	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	24,38	29,69	40,71	11,02	13,64	0,00	0,00	0,00	0,00	168
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,18	0,00	0,00	0,00	0,00	0,00	0,00	1965
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	7,63	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2622
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,13	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2461
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11,02	0,00	0,00	0,00	0,00	0,00	1815
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	28,27	0,00	0,00	708
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	51,13	0,00	
Ovary	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11,02	0,00	0,00	0,00	0,00	0,00	1815
Primary site unknown	0,00	8,48	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,90	10,18	0,00	0,00	0,00	0,00	0,00	0,00	701
SCC of Skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	28,27	0,00	0,00	708
Skin other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,18	0,00	0,00	0,00	0,00	0,00	0,00	1965



Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	28,27	0,00	0,00	708
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,18	0,00	0,00	0,00	0,00	0,00	0,00	1965
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13,64	0,00	0,00	0,00	0,00	1467
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13,64	0,00	0,00	0,00	0,00	1467
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,13	0,00	10,18	11,02	0,00	0,00	0,00	0,00	0,00	682

WHITE FEMALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	62,43	0,00	14,34	14,53	58,33	103,09	101,41	216,83	306,29	353,70	727,35	696,71	989,47	1062,65	1257,76	1442,34	1498,40	4
All sites but C44	62,43	0,00	0,00	14,53	43,75	103,09	101,41	216,83	287,15	335,08	709,17	676,52	968,19	1014,34	1130,57	1290,51	1271,37	4
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,09	0,00	10,64	0,00	14,13	0,00	22,70	591
BCC	0,00	0,00	14,34	0,00	14,58	0,00	0,00	0,00	0,00	9,31	18,18	20,19	10,64	36,23	56,53	75,91	113,52	112
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,64	48,30	14,13	18,98	45,41	274
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,64	0,00	0,00	0,00	0,00	1880
Brain, CNS	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,57	18,62	45,46	10,10	10,64	12,08	14,13	0,00	0,00	166
Breast	0,00	0,00	0,00	0,00	14,58	51,54	67,61	113,13	124,43	167,54	300,03	313,02	393,66	422,64	452,23	474,45	431,36	9
Cervix	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,71	67,00	55,85	72,74	10,10	10,64	36,23	14,13	18,98	22,70	66
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,85	9,57	46,54	63,64	40,39	85,12	120,76	127,19	151,83	68,11	40
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,08	0,00	0,00	0,00	1656
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,09	10,10	10,64	0,00	0,00	0,00	0,00	671
Eye	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,09	0,00	0,00	0,00	14,13	0,00	0,00	862
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,08	14,13	0,00	45,41	764
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,98	0,00
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,14	0,00	0,00	10,10	0,00	24,15	0,00	37,96	0,00	375
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,08	0,00	0,00	0,00	1656
Leukaemia	0,00	0,00	0,00	0,00	0,00	12,89	0,00	0,00	0,00	0,00	0,00	20,19	21,28	12,08	14,13	18,98	22,70	249
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,08	0,00	0,00	0,00	1656
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,31	45,46	40,39	0,00	24,15	28,26	113,87	45,41	136
Lung	20,81	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,09	20,19	21,28	36,23	56,53	151,83	90,81	122
Melanoma	0,00	0,00	0,00	0,00	14,58	12,89	0,00	9,43	0,00	0,00	9,09	40,39	42,56	60,38	56,53	94,89	68,11	82
Mouth	0,00	0,00	0,00	0,00	0,00	12,89	0,00	0,00	0,00	9,31	9,09	10,10	21,28	12,08	28,26	18,98	0,00	195
Myeloma	20,81	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,09	0,00	21,28	12,08	0,00	18,98	0,00	317
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,09	0,00	0,00	0,00	0,00	0,00	22,70	2201
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,57	0,00	18,18	10,10	42,56	24,15	14,13	18,98	0,00	169

Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,98	22,70	
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	11,27	0,00	0,00	0,00	0,00	0,00	0,00	12,08	0,00	0,00	45,41	857
Ovary	0,00	0,00	0,00	0,00	0,00	0,00	11,27	0,00	9,57	0,00	0,00	40,39	31,92	36,23	56,53	37,96	0,00	108
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,43	0,00	9,31	27,28	30,29	21,28	24,15	42,40	18,98	68,11	122
Primary site unknown	20,81	0,00	0,00	14,53	0,00	0,00	0,00	9,43	9,57	18,62	9,09	40,39	63,84	36,23	70,66	0,00	136,22	69
SCC of Skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,64	0,00	56,53	37,96	113,52	298
Skin other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,14	9,31	0,00	0,00	0,00	12,08	14,13	37,96	0,00	366
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,09	0,00	0,00	0,00	14,13	0,00	45,41	862
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,57	0,00	9,09	0,00	42,56	0,00	0,00	0,00	22,70	327
Thyroid	0,00	0,00	0,00	0,00	0,00	12,89	0,00	0,00	0,00	0,00	9,09	10,10	0,00	0,00	0,00	18,98	22,70	624
Tongue	0,00	0,00	0,00	0,00	14,58	0,00	0,00	0,00	0,00	0,00	0,00	0,00	21,28	0,00	14,13	0,00	0,00	401
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,85	19,14	0,00	9,09	20,19	53,20	0,00	56,53	37,96	0,00	113
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,09	0,00	0,00	0,00	0,00	0,00	0,00	2201
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	11,27	0,00	0,00	0,00	9,09	0,00	21,28	12,08	14,13	0,00	22,70	295

ALL MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	6,22	0,64	1,27	2,76	9,66	12,57	15,64	25,34	41,40	96,30	208,73	246,64	427,42	514,99	650,16	656,52	815,18	9
All sites but C44	6,22	0,64	1,27	2,76	8,18	11,31	15,10	23,73	39,36	93,60	200,83	242,71	414,99	488,74	597,92	609,29	708,14	10
Anus	0,00	0,00	0,00	0,00	0,00	0,63	0,54	1,62	2,04	0,90	5,64	0,00	3,11	0,00	2,90	0,00	0,00	1151
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,90	3,38	3,94	6,22	18,18	17,42	18,89	57,64	400
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,68	0,00	4,51	5,25	10,88	6,06	0,00	9,45	24,70	717
Bone	0,00	0,00	0,00	0,00	1,49	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,55	0,00	0,00	0,00	0,00	6579
Brain, CNS	1,24	0,00	0,64	0,00	0,00	0,63	0,54	0,54	0,68	2,70	1,13	0,00	3,11	4,04	2,90	0,00	0,00	1102
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,68	0,00	2,26	0,00	1,55	6,06	8,71	0,00	16,47	1039
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,13	1,31	0,00	0,00	0,00	0,00	0,00	8197
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	2,16	3,24	5,43	16,20	19,18	22,30	38,86	34,33	40,64	23,62	49,40	110
Connective tissue	0,00	0,00	0,00	0,00	0,74	0,00	1,08	0,00	0,68	2,70	1,13	0,00	6,22	2,02	2,90	0,00	0,00	1145
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,00	0,68	0,90	0,00	0,00	0,00	0,00	0,00	4,72	0,00	9434
Eye	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,00	0,68	0,00	0,00	1,31	3,11	0,00	0,00	0,00	0,00	3547
Gum	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,55	0,00	0,00	0,00	0,00	12904
Haematology other	0,00	0,00	0,00	0,00	1,49	0,00	0,00	0,00	0,00	0,00	1,13	0,00	1,55	0,00	0,00	9,45	8,23	4797
Hodgkin lymphoma	0,00	0,00	0,64	0,00	0,74	1,88	2,16	0,54	1,36	0,90	1,13	0,00	3,11	0,00	0,00	4,72	0,00	1606
Ill defined	0,62	0,00	0,00	0,00	0,00	0,00	0,54	0,00	0,00	0,00	1,13	1,31	1,55	2,02	0,00	4,72	0,00	2790
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	0,54	1,62	2,71	1,80	4,51	0,00	3,11	0,00	2,90	0,00	8,23	1164
Kidney	1,87	0,64	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,90	2,62	6,22	4,04	14,51	14,17	8,23	530
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,00	0,00	7,90	14,43	3,11	14,14	8,71	14,17	8,23	410
Leukaemia	0,00	0,00	0,00	0,00	0,74	0,63	0,00	2,16	0,00	0,90	2,26	0,00	0,00	10,10	2,90	4,72	0,00	1016
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,68	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	29412
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	1,26	0,00	0,54	2,04	0,90	5,64	6,56	7,77	18,18	26,12	23,62	0,00	290
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,08	2,04	8,10	13,54	11,81	27,98	26,25	29,03	51,96	8,23	167
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,54	0,00	2,70	6,77	1,31	9,33	8,08	14,51	4,72	65,87	457

Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,31	0,00	2,02	5,81	0,00	24,70	2189
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,68	0,90	1,13	5,25	6,22	4,04	0,00	0,00	8,23	1098	
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,00	2,70	5,64	1,31	1,55	2,02	2,90	4,72	0,00	1201	
Naso-Oropharynx	1,24	0,00	0,00	0,69	0,00	0,00	0,00	0,00	0,00	0,90	2,26	5,25	7,77	4,04	0,00	9,45	8,23	903	
Non Hodgkin lymphoma	0,00	0,00	0,00	0,69	0,00	3,14	1,08	1,62	4,07	6,30	13,54	6,56	9,33	12,12	8,71	9,45	32,94	298	
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,54	0,68	4,50	4,51	23,61	24,87	20,20	20,32	18,89	8,23	201	
Other specified	0,00	0,00	0,00	0,69	0,00	0,63	0,00	0,00	0,68	0,90	1,13	3,94	0,00	2,02	8,71	0,00	0,00	1070	
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,36	2,70	3,38	2,62	9,33	6,06	20,32	9,45	0,00	437	
Penis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,68	3,60	7,90	3,94	3,11	4,04	0,00	0,00	0,00	840	
Primary site unknown	1,24	0,00	0,00	0,69	1,49	0,63	1,62	2,70	4,07	8,10	7,90	5,25	18,65	30,29	11,61	37,79	8,23	213	
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,54	1,08	4,07	22,50	55,29	97,08	186,51	250,43	333,79	340,07	403,47	22	
SCC of Skin	0,00	0,00	0,00	0,00	0,74	0,00	0,54	0,54	0,68	0,90	2,26	0,00	4,66	6,06	26,12	23,62	32,94	471	
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,00	0,00	0,90	0,00	0,00	1,55	2,02	0,00	4,72	8,23	3993	
Skin other	0,00	0,00	0,00	0,00	0,74	1,26	0,00	1,08	1,36	0,90	2,26	0,00	1,55	2,02	8,71	4,72	16,47	1007	
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,00	0,00	0,90	1,13	1,31	3,11	0,00	0,00	0,00	0,00	2862	
Stomach	0,00	0,00	0,00	0,00	0,00	1,26	0,00	2,16	0,68	0,00	5,64	13,12	4,66	8,08	26,12	4,72	8,23	325	
Testis	0,00	0,00	0,00	0,00	1,49	0,63	1,08	1,08	0,00	0,00	1,13	0,00	0,00	0,00	0,00	0,00	0,00	3697	
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,54	0,00	0,00	1,13	2,62	0,00	0,00	0,00	0,00	0,00	4663	
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,04	0,00	2,26	1,31	4,66	6,06	2,90	0,00	0,00	1041	

ASIAN MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	34,85	0,00	30,69	20,69	16,40	15,45	33,01	77,19	45,58	85,00	109,27	298,59	293,46	401,57	0,00	19
All sites but C44	0,00	0,00	34,85	0,00	30,69	20,69	16,40	15,45	33,01	77,19	45,58	85,00	109,27	298,59	220,09	401,57	0,00	21
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,79	0,00	0,00	0,00	0,00	0,00	0,00	878
Bone	0,00	0,00	0,00	0,00	30,69	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	652
Brain, CNS	0,00	0,00	34,85	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	574
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,51	19,30	0,00	0,00	0,00	99,53	0,00	0,00	0,00	148
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	133,86	0,00	
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,30	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1037
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,79	0,00	0,00	0,00	0,00	0,00	0,00	878
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	49,77	0,00	0,00	0,00	402
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	28,33	36,42	0,00	0,00	0,00	0,00	309
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	20,69	0,00	0,00	16,51	0,00	0,00	0,00	36,42	0,00	0,00	0,00	0,00	272
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,30	0,00	0,00	36,42	0,00	0,00	0,00	0,00	359
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,30	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1037
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	149,30	220,09	267,71	0,00	55
SCC of Skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	73,36	0,00	0,00	273
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	15,45	0,00	0,00	0,00	56,67	0,00	0,00	0,00	0,00	0,00	278
Testis	0,00	0,00	0,00	0,00	0,00	0,00	16,40	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1220

BLACK MALES

Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	5,43	0,71	0,72	2,35	5,62	7,93	11,79	21,99	35,16	79,47	149,42	219,76	341,13	416,86	509,04	427,51	762,99	12
All sites but C44	5,43	0,71	0,72	2,35	4,01	7,27	11,22	20,25	32,92	77,51	144,14	219,76	338,80	416,86	503,84	416,83	762,99	12
Anus	0,00	0,00	0,00	0,00	0,00	0,66	0,56	1,16	2,24	0,98	3,97	0,00	4,67	0,00	5,19	0,00	0,00	1030
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,98	1,32	0,00	0,00	0,00	0,00	0,00	0,00	8696
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,58	0,75	0,00	1,32	5,40	2,34	3,28	0,00	0,00	0,00	1464
Bone	0,00	0,00	0,00	0,00	0,80	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	25001
Brain, CNS	1,36	0,00	0,00	0,00	0,00	0,66	0,56	0,00	0,75	1,96	1,32	0,00	0,00	3,28	0,00	0,00	0,00	2023
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,75	0,00	1,32	0,00	2,34	6,56	0,00	0,00	61,04	1824
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,32	0,00	0,00	0,00	0,00	0,00	0,00	15152
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	2,24	2,89	1,50	12,76	6,61	16,21	25,70	36,11	20,78	10,69	30,52	161
Connective tissue	0,00	0,00	0,00	0,00	0,80	0,00	1,12	0,00	0,75	2,94	0,00	0,00	2,34	0,00	0,00	0,00	0,00	2516
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,75	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	26667
Eye	0,00	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,75	0,00	0,00	1,80	4,67	0,00	0,00	0,00	0,00	2571
Haematology other	0,00	0,00	0,00	0,00	0,80	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	25001
Hodgkin lymphoma	0,00	0,00	0,72	0,00	0,00	0,66	1,12	0,58	1,50	0,00	1,32	0,00	2,34	0,00	0,00	0,00	0,00	2428
Ill defined	0,68	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,00	1,32	1,80	2,34	3,28	0,00	0,00	0,00	2005
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,74	2,99	1,96	5,29	0,00	4,67	0,00	5,19	0,00	0,00	916
Kidney	1,36	0,71	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,32	1,80	4,67	0,00	10,39	10,69	0,00	988
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,58	0,00	0,00	9,26	18,01	4,67	9,85	5,19	0,00	0,00	421
Leukaemia	0,00	0,00	0,00	0,00	0,80	0,66	0,00	1,74	0,00	0,00	2,64	0,00	0,00	3,28	0,00	0,00	0,00	2193
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,75	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	26667
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	1,32	0,00	0,58	2,24	0,00	5,29	5,40	9,35	9,85	31,17	10,69	0,00	307
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,58	2,24	7,85	13,22	10,81	23,37	16,41	31,17	32,06	0,00	190
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,64	0,00	0,00	0,00	5,19	0,00	0,00	2555
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,98	1,32	1,80	4,67	3,28	0,00	0,00	30,52	1660
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,58	0,00	2,94	5,29	1,80	0,00	3,28	0,00	10,69	0,00	1440
Naso-Oropharynx	1,36	0,00	0,00	0,78	0,00	0,00	0,00	0,00	0,00	0,98	2,64	7,21	11,68	3,28	0,00	0,00	0,00	717

Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	1,32	1,12	1,74	3,74	6,87	9,26	7,21	7,01	9,85	0,00	0,00	30,52	416
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,58	0,00	4,91	3,97	23,42	37,38	26,26	10,39	21,38	0,00	188
Other specified	0,00	0,00	0,00	0,78	0,00	0,66	0,00	0,00	0,75	0,98	1,32	3,60	0,00	3,28	10,39	0,00	0,00	920
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,75	1,96	1,32	1,80	2,34	0,00	10,39	0,00	0,00	1078
Penis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,58	0,00	3,92	9,26	5,40	4,67	6,56	0,00	0,00	0,00	659
Primary site unknown	0,68	0,00	0,00	0,78	0,00	0,66	1,68	2,89	4,49	4,91	5,29	1,80	9,35	19,69	20,78	21,38	0,00	274
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,56	1,16	2,24	18,64	39,67	91,87	154,21	239,61	306,46	299,26	610,40	24
SCC of Skin	0,00	0,00	0,00	0,00	0,80	0,00	0,56	0,58	0,75	0,00	2,64	0,00	2,34	0,00	0,00	10,69	0,00	2608
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,98	0,00	0,00	2,34	0,00	0,00	0,00	0,00	5155
Skin other	0,00	0,00	0,00	0,00	0,80	0,66	0,00	1,16	1,50	0,98	1,32	0,00	0,00	0,00	5,19	0,00	0,00	1723
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,98	1,32	1,80	2,34	0,00	0,00	0,00	0,00	2858
Stomach	0,00	0,00	0,00	0,00	0,00	0,66	0,00	1,74	0,75	0,00	3,97	9,01	4,67	3,28	25,97	0,00	0,00	400
Testis	0,00	0,00	0,00	0,00	0,80	0,00	0,00	0,00	0,00	0,00	1,32	0,00	0,00	0,00	0,00	0,00	0,00	9434
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,58	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	34483
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,24	0,00	0,00	1,80	4,67	6,56	5,19	0,00	0,00	978



**COLOURED MALES**

Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	0,00	8,06	0,00	0,00	6,19	0,00	0,00	16,72	44,29	41,02	63,42	115,75	31,67	133,66	173,02	62
All sites but C44	0,00	0,00	0,00	8,06	0,00	0,00	6,19	0,00	0,00	16,72	44,29	41,02	63,42	115,75	31,67	133,66	173,02	62
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,68	0,00	0,00	0,00	0,00	1578
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,51	12,68	0,00	0,00	0,00	0,00	603
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	6,19	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3232
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,29	0,00	0,00	0,00	1037
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	66,83	0,00	
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,86	10,25	0,00	57,87	0,00	0,00	0,00	260
Non Hodgkin lymphoma	0,00	0,00	0,00	8,06	0,00	0,00	0,00	0,00	0,00	0,00	26,57	0,00	0,00	19,29	0,00	0,00	173,02	371
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,29	0,00	0,00	0,00	1037
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,72	8,86	10,25	38,05	0,00	31,67	66,83	0,00	190

WHITE MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	20,08	0,00	0,00	0,00	66,52	80,75	59,72	68,84	104,16	162,53	475,50	488,91	1061,48	1175,33	1448,73	1531,94	1841,75	4
All sites but C44	20,08	0,00	0,00	0,00	66,52	69,22	59,72	68,84	104,16	154,41	453,21	463,62	997,97	1043,61	1255,57	1385,27	1509,21	5
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,61	0,00	0,00	7,43	0,00	0,00	0,00	0,00	0,00	0,00	1247
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	14,86	25,29	36,29	91,19	72,44	65,19	179,06	84
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,29	8,43	45,36	20,26	0,00	32,59	76,74	208
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,07	0,00	0,00	0,00	0,00	2206
Brain, CNS	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,61	0,00	8,13	0,00	0,00	18,14	10,13	12,07	0,00	0,00	351
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,43	0,00	0,00	10,13	36,22	0,00	0,00	372
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,43	0,00	0,00	0,00	0,00	0,00	2373
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,61	43,40	32,51	89,16	50,58	117,94	40,53	120,73	65,19	127,90	40
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,43	0,00	27,22	10,13	12,07	0,00	0,00	352
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	9,95	0,00	0,00	8,13	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1107
Gum	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,07	0,00	0,00	0,00	0,00	2206
Haematology other	0,00	0,00	0,00	0,00	13,30	0,00	0,00	0,00	0,00	0,00	7,43	0,00	9,07	0,00	0,00	32,59	25,58	672
Hodgkin lymphoma	0,00	0,00	0,00	0,00	13,30	23,07	19,91	0,00	0,00	0,00	0,00	0,00	9,07	0,00	0,00	16,30	0,00	307
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,30	0,00	
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	25,58	
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,15	8,43	18,14	20,26	36,22	32,59	25,58	167
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,43	0,00	40,53	24,15	48,89	25,58	274
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,61	0,00	8,13	0,00	0,00	0,00	20,26	12,07	16,30	0,00	408
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,13	7,43	16,86	9,07	60,79	36,22	48,89	0,00	145
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,61	0,00	8,13	7,43	8,43	54,43	50,66	48,29	130,38	25,58	108
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	9,95	8,61	0,00	24,38	29,72	8,43	54,43	40,53	48,29	16,30	204,64	90
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,43	0,00	10,13	24,15	0,00	76,74	469
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,68	0,00	0,00	25,29	18,14	10,13	0,00	0,00	0,00	322

Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,07	0,00	12,07	0,00	0,00	947
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,13	0,00	32,59	25,58	1975
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	23,07	0,00	0,00	0,00	0,00	14,86	8,43	18,14	20,26	24,15	32,59	51,16	184	
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	9,95	0,00	8,68	0,00	7,43	42,15	0,00	20,26	60,36	32,59	25,58	135	
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,43	0,00	0,00	12,07	0,00	0,00	976	
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,68	0,00	14,86	8,43	36,29	30,40	60,36	32,59	0,00	126	
Penis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,68	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2305	
Primary site unknown	20,08	0,00	0,00	0,00	26,61	0,00	0,00	0,00	0,00	24,38	22,29	25,29	63,51	81,06	0,00	97,78	25,58	76	
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	26,04	32,51	133,73	177,02	453,62	486,34	627,78	668,19	716,24	11	
SCC of Skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,13	0,00	0,00	18,14	30,40	96,58	65,19	102,32	131	
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,13	0,00	16,30	25,58	1975	
Skin other	0,00	0,00	0,00	0,00	0,00	11,54	0,00	0,00	0,00	0,00	7,43	0,00	9,07	10,13	24,15	16,30	51,16	321	
Stomach	0,00	0,00	0,00	0,00	0,00	11,54	0,00	0,00	0,00	0,00	14,86	25,29	9,07	30,40	48,29	16,30	25,58	144	
Testis	0,00	0,00	0,00	0,00	13,30	11,54	9,95	17,21	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	385	
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,43	16,86	0,00	0,00	0,00	0,00	0,00	824	
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	14,86	0,00	9,07	10,13	0,00	0,00	0,00	588	

## Frequency of Cancer by Age Group

ALL FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	2318	0	16	7	8	5	14	39	93	179	272	248	279	253	262	192	203	136	112
All sites but C44	2241	0	16	7	6	5	13	38	92	175	260	246	273	247	258	187	192	126	100
Anus	26	0	0	0	0	0	0	0	3	4	4	6	3	0	1	1	1	2	1
BCC	32	0	0	0	1	0	1	1	0	0	4	1	3	3	1	3	5	4	5
Bladder	20	0	0	0	0	0	0	0	0	0	1	3	0	1	3	6	2	2	2
Bone	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Brain, CNS	21	0	3	1	1	0	0	0	0	0	1	3	5	2	1	2	1	0	1
Breast	648	0	0	0	0	0	5	8	23	70	75	68	76	75	67	61	55	33	32
Burkitt lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Cervix	572	0	0	0	0	0	0	4	34	56	94	100	77	67	52	32	29	15	12
Colorectal	134	0	0	0	0	1	0	1	1	7	10	9	14	12	24	20	16	14	5
Connective tissue	9	0	0	0	0	0	0	1	0	1	1	0	0	1	2	1	1	1	0
Endocrine	7	0	0	0	1	0	0	0	0	2	0	1	1	1	1	0	0	0	0
Eye	8	0	1	0	1	0	0	0	0	0	2	1	1	0	1	0	1	0	0
Haematology other	7	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	2	0	2
Hodgkin lymphoma	14	0	0	1	0	0	2	2	0	0	1	1	4	2	0	0	0	1	0
Ill defined	9	0	0	0	0	0	0	0	0	1	1	1	3	0	1	0	1	0	1
Kaposi Sarcoma	10	0	0	0	0	0	0	2	2	2	3	1	0	0	0	0	0	0	0
Kidney	19	0	1	3	0	0	1	0	0	0	4	1	2	1	1	2	1	2	0
Larynx	5	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	1	0	0

Leukaemia	21	0	3	0	0	0	0	2	1	0	0	1	0	3	2	2	1	3	3
Lip	3	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	0
Liver & Bile duct	43	0	0	0	0	0	0	0	0	1	1	1	9	9	1	4	7	7	3
Lung	49	0	1	0	1	0	0	0	0	0	1	2	2	5	5	6	8	12	6
Melanoma	36	0	0	0	1	0	1	1	0	2	0	1	1	5	5	5	6	5	3
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Mouth	18	0	0	0	0	0	0	1	0	1	0	1	2	3	4	2	3	1	0
Myeloma	14	0	1	0	0	0	0	1	1	0	1	0	2	1	3	2	0	1	1
Naso-Oropharynx	11	0	0	0	0	0	0	0	0	1	1	3	3	0	2	0	0	0	1
Non Hodgkin lymphoma	33	0	1	0	0	0	0	3	3	1	2	2	4	4	8	3	1	1	0
Oesophagus	34	0	0	0	0	0	0	0	1	0	0	5	3	5	5	5	2	7	1
Other specified	17	0	0	0	0	0	0	0	1	1	4	2	2	1	1	3	0	0	2
Ovary	44	0	0	0	0	0	0	1	1	3	3	1	3	10	6	6	6	3	1
Pancreas	31	1	0	0	0	0	0	0	1	1	2	1	4	5	3	3	4	3	3
Placenta	3	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0
Primary site unknown	107	0	5	1	1	3	0	3	6	6	8	9	11	15	16	6	10	0	7
SCC of Skin	28	0	0	0	0	0	0	0	1	3	5	0	1	2	2	0	5	4	5
Salivary gland	3	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0
Skin other	17	0	0	0	1	0	0	0	0	1	3	1	2	1	1	2	1	2	2
Small intestine	7	0	0	0	0	0	0	1	0	0	0	0	2	0	1	0	1	0	2
Stomach	23	0	0	0	0	0	0	1	0	0	1	4	4	1	6	1	3	0	2
Thyroid	17	0	0	0	0	0	0	3	2	2	2	1	3	1	1	0	0	1	1
Tongue	11	0	0	0	0	0	1	0	1	1	2	0	2	0	3	0	1	0	0
Uterus	97	0	0	0	0	0	0	0	0	2	5	5	7	8	22	10	24	8	6
Vagina	12	0	0	0	0	0	0	0	0	0	2	1	5	0	3	0	0	0	1

ASIAN FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	39	0	0	0	0	0	1	0	1	2	5	0	5	7	5	4	7	2	0
All sites but C44	39	0	0	0	0	0	1	0	1	2	5	0	5	7	5	4	7	2	0
Breast	16	0	0	0	0	0	0	0	0	1	4	0	2	2	1	3	2	1	0
Cervix	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Colorectal	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	0
Connective tissue	3	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0
Hodgkin lymphoma	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Lung	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Myeloma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Primary site unknown	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Stomach	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
Thyroid	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Uterus	4	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0
Vulva	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0

BLACK FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	1539	0	12	6	7	4	9	30	83	153	224	200	181	170	161	98	102	55	44
All sites but C44	1508	0	12	6	6	4	9	29	82	149	214	200	178	166	159	97	102	53	42
Anus	22	0	0	0	0	0	0	0	3	4	4	6	2	0	0	1	0	2	0
BCC	7	0	0	0	0	0	0	1	0	0	4	0	1	1	0	0	0	0	0
Bladder	9	0	0	0	0	0	0	0	0	0	1	2	0	1	2	2	1	0	0
Brain, CNS	9	0	3	1	1	0	0	0	0	0	0	1	0	1	0	1	0	0	1
Breast	348	0	0	0	0	0	4	4	17	57	53	48	38	39	29	22	20	6	11
Burkitt lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Cervix	524	0	0	0	0	0	0	4	34	52	82	90	65	65	50	29	28	14	11
Colorectal	72	0	0	0	0	1	0	1	1	5	9	4	5	8	15	10	5	6	2
Connective tissue	5	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	1	1	0
Endocrine	3	0	0	0	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0
Eye	6	0	1	0	1	0	0	0	0	0	2	1	0	0	1	0	0	0	0
Haematology other	3	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0
Hodgkin lymphoma	11	0	0	1	0	0	1	1	0	0	1	1	4	2	0	0	0	0	0
Ill defined	9	0	0	0	0	0	0	0	0	1	1	1	3	0	1	0	1	0	1
Kaposi Sarcoma	9	0	0	0	0	0	0	2	2	2	2	1	0	0	0	0	0	0	0
Kidney	11	0	0	3	0	0	1	0	0	0	2	1	2	0	1	0	1	0	0
Larynx	4	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	1	0	0
Leukaemia	12	0	3	0	0	0	0	1	1	0	0	1	0	1	0	1	0	2	2

Lip	2	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0
Liver & Bile duct	20	0	0	0	0	0	0	0	0	1	1	0	4	4	1	2	5	1	1
Lung	21	0	0	0	1	0	0	0	0	0	1	2	1	1	3	2	4	4	2
Melanoma	7	0	0	0	1	0	0	0	0	1	0	1	0	1	1	0	2	0	0
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Mouth	7	0	0	0	0	0	0	0	0	1	0	0	1	2	2	1	0	0	0
Myeloma	7	0	0	0	0	0	0	1	1	0	1	0	1	1	1	0	0	0	1
Naso-Oropharynx	9	0	0	0	0	0	0	0	0	1	1	3	2	0	2	0	0	0	0
Non Hodgkin lymphoma	21	0	1	0	0	0	0	3	3	1	1	2	2	3	4	1	0	0	0
Oesophagus	31	0	0	0	0	0	0	0	1	0	0	5	3	5	5	5	2	5	0
Other specified	12	0	0	0	0	0	0	0	0	1	4	1	2	1	1	2	0	0	0
Ovary	25	0	0	0	0	0	0	1	0	3	2	1	3	5	3	3	2	1	1
Pancreas	9	0	0	0	0	0	0	0	1	0	2	0	0	1	1	1	1	2	0
Placenta	3	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0
Primary site unknown	71	0	4	0	1	2	0	3	6	5	7	5	8	11	10	3	5	0	1
SCC of Skin	15	0	0	0	0	0	0	0	1	3	5	0	1	2	1	0	0	2	0
Salivary gland	3	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0
Skin other	9	0	0	0	1	0	0	0	0	1	1	0	1	1	1	1	0	0	2
Small intestine	3	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0	0
Stomach	13	0	0	0	0	0	0	1	0	0	0	4	3	1	1	1	1	0	1
Thyroid	11	0	0	0	0	0	0	2	1	2	2	1	2	0	1	0	0	0	0
Tongue	6	0	0	0	0	0	0	0	1	1	2	0	1	0	1	0	0	0	0
Uterus	74	0	0	0	0	0	0	0	0	0	3	5	5	5	15	10	19	6	6
Vagina	10	0	0	0	0	0	0	0	0	0	2	1	4	0	2	0	0	0	1
Vulva	84	0	0	0	0	0	1	2	9	8	26	10	13	7	4	0	1	3	0



COLOURED FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	48	0	0	1	0	0	0	1	0	0	9	7	12	7	3	1	4	2	1
All sites but C44	45	0	0	1	0	0	0	1	0	0	9	7	11	7	3	1	2	2	1
BCC	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Bladder	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Breast	15	0	0	0	0	0	0	0	0	0	4	2	3	3	0	1	0	1	1
Cervix	12	0	0	0	0	0	0	0	0	0	3	3	4	1	1	0	0	0	0
Colorectal	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Hodgkin lymphoma	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Kaposi Sarcoma	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Liver & Bile duct	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Oesophagus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Ovary	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Primary site unknown	3	0	0	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
SCC of Skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Skin other	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Stomach	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Uterus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Vagina	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Vulva	3	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0

WHITE FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	680	0	3	0	1	1	4	8	9	23	32	38	80	69	93	88	89	76	66
All sites but C44	637	0	3	0	0	1	3	8	9	23	30	36	78	67	91	84	80	68	56
Anus	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1
BCC	24	0	0	0	1	0	1	0	0	0	0	1	2	2	1	3	4	4	5
Bladder	9	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4	1	1	2
Bone	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Brain, CNS	12	0	0	0	0	0	0	0	0	0	1	2	5	1	1	1	1	0	0
Breast	266	0	0	0	0	0	1	4	6	12	13	18	33	31	37	35	32	25	19
Cervix	33	0	0	0	0	0	0	0	0	4	7	6	8	1	1	3	1	1	1
Colorectal	57	0	0	0	0	0	0	0	0	2	1	5	7	4	8	10	9	8	3
Connective tissue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Endocrine	3	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0
Eye	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0
Haematology other	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2
Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Kidney	7	0	0	0	0	0	0	0	0	0	2	0	0	1	0	2	0	2	0
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Leukaemia	9	0	0	0	0	0	0	1	0	0	0	0	0	2	2	1	1	1	1
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0

Liver & Bile duct	22	0	0	0	0	0	0	0	0	0	0	0	1	5	4	0	2	2	6	2
Lung	25	0	1	0	0	0	0	0	0	0	0	0	0	1	2	2	3	4	8	4
Melanoma	29	0	0	0	0	0	1	1	0	1	0	0	1	4	4	5	4	5	5	3
Mouth	10	0	0	0	0	0	0	1	0	0	0	1	1	1	2	1	2	1	0	
Myeloma	6	0	1	0	0	0	0	0	0	0	0	0	1	0	2	1	0	1	0	
Naso-Oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
Non Hodgkin lymphoma	12	0	0	0	0	0	0	0	0	0	1	0	2	1	4	2	1	1	0	
Oesophagus	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Other specified	4	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	2
Ovary	18	0	0	0	0	0	0	0	1	0	1	0	0	4	3	3	4	2	0	
Pancreas	19	0	0	0	0	0	0	0	0	1	0	1	3	3	2	2	3	1	3	
Primary site unknown	31	0	1	0	0	1	0	0	0	1	1	2	1	4	6	3	5	0	6	
SCC of Skin	12	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	2	5	
Skin other	7	0	0	0	0	0	0	0	0	0	2	1	0	0	0	1	1	2	0	
Small intestine	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	2	
Stomach	7	0	0	0	0	0	0	0	0	0	1	0	1	0	4	0	0	0	1	
Thyroid	5	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	1	1	
Tongue	4	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0	1	0	0	
Uterus	18	0	0	0	0	0	0	0	0	2	2	0	1	2	5	0	4	2	0	
Vagina	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	
Vulva	7	0	0	0	0	0	0	0	1	0	0	0	1	0	2	1	1	0	1	

ALL MALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	1659	0	10	1	2	4	13	20	29	47	61	107	185	188	275	255	224	139	99
All sites but C44	1573	0	10	1	2	4	11	18	28	44	58	104	178	185	267	242	206	129	86
Anus	17	0	0	0	0	0	0	1	1	3	3	1	5	0	2	0	1	0	0
BCC	37	0	0	0	0	0	0	0	0	0	0	1	3	3	4	9	6	4	7
Bladder	25	0	0	0	0	0	0	0	0	1	1	0	4	4	7	3	0	2	3
Bone	3	0	0	0	0	0	2	0	0	0	0	0	0	0	1	0	0	0	0
Brain, CNS	16	0	2	0	1	0	0	1	1	1	1	3	1	0	2	2	1	0	0
Breast	12	0	0	0	0	0	0	0	0	0	1	0	2	0	1	3	3	0	2
Burkitt lymphoma	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0
Colorectal	137	0	0	0	0	0	0	0	4	6	8	18	17	17	25	17	14	5	6
Connective tissue	14	0	0	0	0	0	1	0	2	0	1	3	1	0	4	1	1	0	0
Endocrine	4	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	1	0
Eye	5	0	0	0	0	0	0	0	1	0	1	0	0	1	2	0	0	0	0
Gum	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Haematology other	7	0	0	0	0	0	2	0	0	0	0	0	1	0	1	0	0	2	1
Hodgkin lymphoma	17	0	0	0	1	0	1	3	4	1	2	1	1	0	2	0	0	1	0
Ill defined	7	0	1	0	0	0	0	0	1	0	0	0	1	1	1	1	0	1	0
Kaposi Sarcoma	18	0	0	0	0	0	0	0	1	3	4	2	4	0	2	0	1	0	1
Kidney	28	0	3	1	0	0	0	0	0	0	0	0	7	2	4	2	5	3	1

Larynx	35	0	0	0	0	0	0	0	0	0	1	0	0	7	11	2	7	3	3	1
Leukaemia	16	0	0	0	0	0	0	1	1	0	4	0	1	2	0	0	5	1	1	0
Lip	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Liver & Bile duct	45	0	0	0	0	0	0	0	2	0	1	3	1	5	5	5	9	9	5	0
Lung	88	0	0	0	0	0	0	0	0	0	2	3	9	12	9	18	13	10	11	1
Melanoma	36	0	0	0	0	0	0	0	0	1	1	0	3	6	1	6	4	5	1	8
Mesothelioma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	2	0	3
Mouth	14	0	0	0	0	0	0	0	0	0	0	1	1	1	4	4	2	0	0	1
Myeloma	14	0	0	0	0	0	0	0	0	0	1	0	3	5	1	1	1	1	1	0
Naso-Oropharynx	20	0	2	0	0	1	0	0	0	0	0	0	1	2	4	5	2	0	2	1
Non Hodgkin lymphoma	62	0	0	0	0	1	0	5	2	3	6	7	12	5	6	6	3	2	4	4
Oesophagus	68	0	0	0	0	0	0	0	1	1	1	1	5	4	18	16	10	7	4	1
Other specified	12	0	0	0	0	1	0	1	0	0	0	1	1	1	3	0	1	3	0	0
Pancreas	28	0	0	0	0	0	0	0	0	0	0	2	3	3	2	6	3	7	2	0
Penis	20	0	0	0	0	0	0	0	0	0	1	1	4	7	3	2	2	0	0	0
Primary site unknown	80	0	2	0	0	1	2	1	3	5	6	9	7	4	12	15	4	8	8	1
Prostate	637	0	0	0	0	0	0	0	1	2	6	25	49	74	120	124	115	72	49	49
SCC of Skin	31	0	0	0	0	0	1	0	1	1	1	1	2	0	3	3	9	5	4	4
Salivary gland	6	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	1	0	1	1
Skin other	18	0	0	0	0	0	1	2	0	2	2	1	2	0	1	1	3	1	2	2
Small intestine	6	0	0	0	0	0	0	0	1	0	0	1	1	1	2	0	0	0	0	0
Stomach	40	0	0	0	0	0	0	2	0	4	1	0	5	10	3	4	9	1	1	1
Testis	8	0	0	0	0	0	2	1	2	2	0	0	1	0	0	0	0	0	0	0
Thyroid	4	0	0	0	0	0	0	0	0	1	0	0	1	2	0	0	0	0	0	0
Tongue	13	0	0	0	0	0	0	0	0	0	0	3	0	2	1	3	3	1	0	0

ASIAN MALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	32	0	0	0	1	0	1	1	1	1	2	4	2	3	3	6	4	3	0
All sites but C44	31	0	0	0	1	0	1	1	1	1	2	4	2	3	3	6	3	3	0
Anus	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Bone	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Brain, CNS	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Colorectal	4	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	0	0	0
Endocrine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Kidney	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Lung	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0
Non Hodgkin lymphoma	3	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	0	0
Pancreas	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
Primary site unknown	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Prostate	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3	2	0
SCC of Skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Stomach	3	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0
Testis	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0

BLACK MALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	890	0	8	1	1	3	7	12	21	38	47	81	113	122	146	127	98	40	25
All sites but C44	871	0	8	1	1	3	5	11	20	35	44	79	109	122	145	127	97	39	25
Anus	14	0	0	0	0	0	0	1	1	2	3	1	3	0	2	0	1	0	0
BCC	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
Bladder	8	0	0	0	0	0	0	0	0	1	1	0	1	3	1	1	0	0	0
Bone	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Brain, CNS	9	0	2	0	0	0	0	1	1	0	1	2	1	0	0	1	0	0	0
Breast	7	0	0	0	0	0	0	0	0	0	1	0	1	0	1	2	0	0	2
Burkitt lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Colorectal	66	0	0	0	0	0	0	0	4	5	2	13	5	9	11	11	4	1	1
Connective tissue	8	0	0	0	0	0	1	0	2	0	1	3	0	0	1	0	0	0	0
Endocrine	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Eye	5	0	0	0	0	0	0	0	1	0	1	0	0	1	2	0	0	0	0
Haematology other	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	9	0	0	0	1	0	0	1	2	1	2	0	1	0	1	0	0	0	0
Ill defined	6	0	1	0	0	0	0	0	1	0	0	0	1	1	1	1	0	0	0
Kaposi Sarcoma	16	0	0	0	0	0	0	0	0	3	4	2	4	0	2	0	1	0	0
Kidney	10	0	2	1	0	0	0	0	0	0	0	0	1	1	2	0	2	1	0
Larynx	24	0	0	0	0	0	0	0	0	1	0	0	7	10	2	3	1	0	0
Leukaemia	8	0	0	0	0	0	1	1	0	3	0	0	2	0	0	1	0	0	0
Lip	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Liver & Bile duct	27	0	0	0	0	0	0	2	0	1	3	0	4	3	4	3	6	1	0

Lung	52	0	0	0	0	0	0	0	0	0	1	3	8	10	6	10	5	6	3	0
Melanoma	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0
Mouth	7	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	1	0	0	1
Myeloma	11	0	0	0	0	0	0	0	0	1	0	3	4	1	0	1	0	1	0	
Naso-Oropharynx	16	0	2	0	0	1	0	0	0	0	0	1	2	4	5	1	0	0	0	
Non Hodgkin lymphoma	37	0	0	0	0	0	0	2	2	3	5	7	7	4	3	3	0	0	1	
Oesophagus	50	0	0	0	0	0	0	0	0	1	0	5	3	13	16	8	2	2	0	
Other specified	10	0	0	0	0	1	0	1	0	0	1	1	1	2	0	1	2	0	0	
Pancreas	8	0	0	0	0	0	0	0	0	0	1	2	1	1	1	0	2	0	0	
Penis	19	0	0	0	0	0	0	0	0	1	0	4	7	3	2	2	0	0	0	
Primary site unknown	43	0	1	0	0	1	0	1	3	5	6	5	4	1	4	6	4	2	0	
Prostate	352	0	0	0	0	0	0	0	1	2	3	19	30	51	66	73	59	28	20	
SCC of Skin	8	0	0	0	0	0	1	0	1	1	1	1	0	2	0	1	0	0	1	0
Salivary gland	3	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	
Skin other	9	0	0	0	0	0	1	1	0	2	2	1	1	0	0	0	1	0	0	
Small intestine	5	0	0	0	0	0	0	0	1	0	0	1	1	1	1	0	0	0	0	
Stomach	21	0	0	0	0	0	0	1	0	3	1	0	3	5	2	1	5	0	0	
Testis	2	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	
Thyroid	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	
Tongue	9	0	0	0	0	0	0	0	0	0	0	3	0	0	1	2	2	1	0	0



COLOURED MALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	28	0	0	0	0	1	0	0	1	0	0	2	5	4	5	6	1	2	1
All sites but C44	28	0	0	0	0	1	0	0	1	0	0	2	5	4	5	6	1	2	1
Bladder	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Colorectal	3	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0
Kaposi Sarcoma	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Liver & Bile duct	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Lung	5	0	0	0	0	0	0	0	0	0	0	0	1	1	0	3	0	0	0
Non Hodgkin lymphoma	6	0	0	0	0	1	0	0	0	0	0	0	3	0	0	1	0	0	1
Primary site unknown	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Prostate	9	0	0	0	0	0	0	0	0	0	0	2	1	1	3	0	1	1	0

WHITE MALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	700	0	1	0	0	0	5	7	6	8	12	20	64	58	117	116	120	94	72
All sites but C44	634	0	1	0	0	0	5	6	6	8	12	19	61	55	110	103	104	85	59
Anus	2	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0
BCC	35	0	0	0	0	0	0	0	0	0	0	0	2	3	4	9	6	4	7
Bladder	16	0	0	0	0	0	0	0	0	0	0	0	3	1	5	2	0	2	3
Bone	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Brain, CNS	6	0	0	0	0	0	0	0	0	1	0	1	0	0	2	1	1	0	0
Breast	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	3	0	0
Burkitt lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Colorectal	64	0	0	0	0	0	0	0	0	1	5	4	12	6	13	4	10	4	5
Connective tissue	6	0	0	0	0	0	0	0	0	0	0	0	1	0	3	1	1	0	0
Endocrine	2	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0
Gum	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Haematology other	6	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	2	1
Hodgkin lymphoma	7	0	0	0	0	0	1	2	2	0	0	0	0	0	1	0	0	1	0
Ill defined	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Kaposi Sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Kidney	16	0	0	0	0	0	0	0	0	0	0	0	5	1	2	2	3	2	1
Larynx	11	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	2	3	1
Leukaemia	6	0	0	0	0	0	0	0	0	1	0	1	0	0	0	2	1	1	0

Liver & Bile duct	17	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1	6	3	3	0
Lung	28	0	0	0	0	0	0	0	0	1	0	1	1	1	6	5	4	8	1	
Melanoma	33	0	0	0	0	0	0	0	1	1	0	3	4	1	6	4	4	1	8	
Mesothelioma	7	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	2	0	3	
Mouth	7	0	0	0	0	0	0	0	0	0	1	0	0	3	2	1	0	0	0	
Myeloma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	
Naso-Oropharynx	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	1	
Non Hodgkin lymphoma	15	0	0	0	0	0	0	2	0	0	0	0	2	1	2	2	2	2	2	
Oesophagus	18	0	0	0	0	0	0	0	1	0	1	0	1	5	0	2	5	2	1	
Other specified	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	
Pancreas	18	0	0	0	0	0	0	0	0	0	1	0	2	1	4	3	5	2	0	
Penis	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	
Primary site unknown	34	0	1	0	0	0	2	0	0	0	0	3	3	3	7	8	0	6	1	
Prostate	265	0	0	0	0	0	0	0	0	0	3	4	18	21	50	48	52	41	28	
SCC of Skin	22	0	0	0	0	0	0	0	0	0	0	1	0	0	2	3	8	4	4	
Salivary gland	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	
Skin other	9	0	0	0	0	0	0	1	0	0	0	0	1	0	1	1	2	1	2	
Stomach	16	0	0	0	0	0	0	1	0	0	0	0	2	3	1	3	4	1	1	
Testis	5	0	0	0	0	0	1	1	1	2	0	0	0	0	0	0	0	0	0	
Thyroid	3	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	
Tongue	4	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0	0	0	